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A B S T R A C T
Melanocortin peptides induce neuroprotection in acute and chronic experimental neurodegenerative
conditions. Melanocortins likewise counteract systemic responses to brain injuries. Furthermore, they
promote neurogenesis by activating critical signaling pathways. Melanocortin-induced long-lasting
improvement in synaptic activity and neurological performance, including learning and memory,
sensory-motor orientation and coordinated limb use, has been consistently observed in experimental
models of acute and chronic neurodegeneration. Evidence indicates that the neuroprotective and
neurogenic effects of melanocortins, as well as the protection against systemic responses to a brain
injury, are mediated by brain melanocortin 4 (MC4) receptors, through an involvement of the vagus nerve.
Here we discuss the targets and mechanisms underlying the multiple beneﬁcial effects recently observed
in animal models of neurodegeneration. We comment on the potential clinical usefulness of
melanocortin MC4 receptor agonists as neuroprotective and neuroregenerative agents in ischemic
stroke, subarachnoid hemorrhage, traumatic brain injury, spinal cord injury, and Alzheimer’s disease.
© 2016 Elsevier Ltd. All rights reserved.
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Acute neurodegenerative conditions including stroke (ischemic
or hemorrhagic), traumatic brain injury (TBI), spinal cord injury
(SCI), and chronic neurodegenerative disorders such as Alz-
heimer’s disease (AD), Parkinson’s disease, amyotrophic lateral
sclerosis, and more, are responsible for high mortality and
disability. Unfortunately, acute and chronic neurodegenerative
disorders have no effective treatment options, as current therapies
only relieve symptoms (with varying effectiveness, depending on
the condition of individual patients), without counteracting the
degenerative process progression (Adams et al., 2007; Antel et al.,
2012; Banerjee et al., 2010; Bragge et al., 2012; Galimberti et al.,
2013; Iqbal and Grundke-Iqbal, 2011; Laskowitz and Kolls, 2010;
Lazarov et al., 2010; Loane and Faden, 2010; Tayeb et al., 2012; Van
der Walt et al., 2010; Zhang and Chopp, 2009). Thus, these diseases
bear a very high cost in both economic terms and life quality
deterioration. A recent study by the European Brain Council
estimated the total cost (direct and indirect) of brain disorders in
Europe was about 800 billion euros in 2010, and neurodegenera-
tive diseases account for a very large proportion (Gustavsson et al.,
2011).
Preclinical investigations aimed at developing novel therapeu-
tics for neurodegenerative disorders indicate that melanocortins
could be promising drug candidates. The melanocortin family
encompasses adrenocorticotropic hormone (ACTH), a-, b- and
g-melanocyte-stimulating hormones (a-, b- and g-MSH) and
shorter fragments: all are products of the pro-opiomelanocortin
gene, and all melanocortins share a core sequence of four amino
acids, His-Phe-Arg-Trp, which are the residues (6–9) in ACTH and
a-MSH (Brzoska et al., 2008; Caruso et al., 2014; Catania et al.,
2004; Getting, 2006; Giuliani et al., 2012; Schiöth, 2001; Versteeg
et al., 1998; Wikberg and Mutulis, 2008). Intensive preclinical
research by several independent groups started in the ﬁfties of the
last century, as well as more recent clinical investigations, showed
many extra-hormonal effects of melanocortins: in this research
ﬁeld, the studies by the pharmacological schools of Modena (Italy)
and Utrecht (The Netherlands) have given an important propul-
sion. Indeed, a growing body of evidence indicates that melano-
cortin peptides and synthetic analogs affect many central and
peripheral body functions, such as food intake, sexual behavior,
pain sensitivity, fever control, pigmentation, learning and memory
(Bertolini et al., 1969, 1986; Brzoska et al., 2008; Catania et al.,
2004; de Wied, 1969; de Wied and Bohus, 1966; Diano, 2011;
Ferrari, 1958; Ferrari et al., 1963; Getting, 2006; Gispen et al., 1970;
O’Donohue and Dorsa, 1982; Schiöth, 2001; Tatro and Sinha, 2003;
Vergoni and Bertolini, 2000; Wikberg and Mutulis, 2008). Of note,
melanocortins also play a protective and life-saving role in
experimental hypoxic and degenerative conditions (Altavilla
et al., 1998; Bazzani et al., 2001, 2002; Bertolini, 1995; Bertolini
et al., 1989; Giuliani et al., 2007a, 2010, 2012; Guarini et al., 1990,
1996, 1997, 2004; Jochem, 2004; Lonati et al., 2012; Minutoli et al.,2011a, 2011b; Mioni et al., 2003; Ottani et al., 2013, 2014; Versteeg
et al., 1998), including acute and chronic neurodegenerative
disorders (Catania, 2008; Corander et al., 2009; Gatti et al.,
2012; Giuliani et al., 2006a, 2006b, 2007b, 2009, 2011, 2012, 2014a,
2014b, 2015; Holloway et al., 2011; Lasaga et al., 2008).
In the present paper we review the protective actions of
melanocortins in the experimental neurodegenerative conditions
thus far investigated, including mechanisms of action, and discuss
the possibility to extend the use of melanocortin agonists for
treatment of other neurodegenerative disorders.
2. Neurodegeneration, endogenous compensation and brain
repair
Impairment in cognitive, behavioral, motor and basic vital
functions are common in patients with neurodegenerative disease.
The broad variety of neurodegenerative phenotypes is consistent
with differences in the initial disease triggers and pathological
hallmark biomarkers of the disease. However, despite differences
in origins, many disease-related pathways that cause neuronal
damage and death are common to most acute and chronic
neurodegenerative disorders (Antel et al., 2012; Banerjee et al.,
2010; Blennow, 2010; Bragge et al., 2012; Drouin-Ouellet and
Cicchetti, 2012; Dumont et al., 2001; Friedlander, 2003; Gao et al.,
2012; Glass et al., 2010; Haass, 2010; Heneka et al., 2015; Iqbal and
Grundke-Iqbal, 2011; Karbowski and Neutzner, 2012; Kumar and
Loane, 2012; Leker and Shohami, 2002; Leuner et al., 2012; Lo,
2010; Loane and Faden, 2010; Mehta et al., 2013; Moskowitz et al.,
2010; Walsh et al., 2014; Yuan and Yankner, 2000; Zipp and Aktas,
2006). It has been hypothesized that the spread of neuro-
degeneration occurs not only by proximity, but also transneuro-
nally through propagation of toxic molecules along network
connections (Guo and Lee, 2014; Raj et al., 2012; Zhou et al., 2012).
Therefore, over the last decades, signiﬁcant progress has been
made in the understanding of pathophysiological mechanisms of
neurodegeneration. In particular, the discovery of the important
role played by excitotoxicity, oxidative stress, mitochondrial
dysfunction, inﬂammatory response, defective autophagy and
apoptosis provided potential targets for novel neuroprotective
drugs. There is evidence that also astrocyte dysfunction can play a
pivotal role in neurological disorders (Sofroniew, 2015). Epigenetic
mechanisms — that is, various types of reversible DNA aberrant
methylation and histone modiﬁcations — have been recently
considered to be involved in neurodegeneration. Consistently,
methyl donors and histone deacetylase inhibitors are under
investigation in treatment of neurodegenerative disorders (Adwan
and Zawia, 2013; Jakovcevski and Akbarian, 2012; Lardenoije et al.,
2015).
Notably, neurodegenerative stimuli also induce endogenous
compensation and brain repair, through mechanisms that could
likewise be implemented as novel drugs. Such endogenous
mechanisms include triggering of neuroprotective pathways,
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and remodelling of discrete networks (Banerjee et al., 2010;
Drouin-Ouellet and Cicchetti, 2012; Giuliani et al., 2010, 2012;
Iqbal and Grundke-Iqbal, 2011; Lo, 2010; Moskowitz et al., 2010;
Walsh et al., 2014; Zhang et al., 2011; Zipp and Aktas, 2006).
Intense basic and clinical investigations are aimed at develop-
ing effective neuroprotective strategies (pharmacological and not
pharmacological), mainly targeting the pathophysiological path-
ways that lead to neurodegeneration. However, no novel drug so
far, despite promising preclinical data, has revealed successful in
large clinical trials, mainly because of toxic side effects, narrow
therapeutic treatment window (for acute disorders) and blockade
of single molecular pathways responsible for neuronal damage
(Adams et al., 2007; Baldwin et al., 2010; Banerjee et al., 2010;
Blennow, 2010; Bragge et al., 2012; Ehrenreich et al., 2009;
Galimberti et al., 2013; Gladstone et al., 2002; Iqbal and Grundke-
Iqbal, 2011; Kumar and Loane, 2012; Laskowitz and Kolls, 2010;
Leker and Shohami, 2002; Lo, 2010; Loane and Faden, 2010;
Moskowitz et al., 2010; O’Collins et al., 2006; Rogalewski et al.,
2006; Schiöth et al., 2012; Schumacher et al., 2014; Spence and
Voskuhl, 2012; Stetler et al., 2014; Tayeb et al., 2012; Van der Walt
et al., 2010; Yepes et al., 2009; Zigmond and Smeyne, 2014; Zipp
and Aktas, 2006).
Neurogenesis, a component of brain plasticity, is a signiﬁcant
endogenous mechanisms of compensation and repair. It is now
recognized that neural stem cells occur in the central nervous
system (CNS) of all adult mammals, including humans. New neural
progenitors are mainly produced in two brain regions, the
subventricular zone (SVZ) of the lateral ventricles and the
subgranular zone (SGZ) of the hippocampal dentate gyrus (DG).
Additional neuronal progenitors have been found in the forebrain
parenchyma, posterior periventricular region surrounding the
hippocampus and spinal cord (Benarroch, 2013; Duan et al., 2008;
Gage, 2000; Iqbal and Grundke-Iqbal, 2011; Lichtenwalner and
Parent, 2006; Lie et al., 2004; Lo, 2010; Suh et al., 2009; Wiltrout
et al., 2007). Interestingly, a recent study on the food chain (plants
 herbivorous animals  humans), based on the principle that
atmosphere 14C is incorporated into DNA during cell division,
indicates that about 1400 DG cells were born daily in the human
brain, and approximately 80% of human DG neurons undergo
renewal in adulthood (Spalding et al., 2013). Conversely in mice
such a renewal only occurs in about 10% of DG neurons (Imayoshi
et al., 2008). Growing evidence indicates that generation of new
neurons can increase under physiological stimuli (e.g., physical
exercise, environmental enrichment, etc.), as well as in pathologi-
cal conditions including acute and chronic neurodegenerative
diseases such as ischemic and hemorrhagic stroke, TBI, SCI, AD to
compensate neuronal loss (Arvidsson et al., 2002; Deng et al., 2010;
Duan et al., 2008; Gage, 2000; Kazanis, 2009; Lazarov et al., 2010;
Lichtenwalner and Parent, 2006; Lie et al., 2004; Liu et al., 1998;Table 1
Melanocortin receptor (MC) subtypes, prevalent distribution and afﬁnity of MC agonis
Receptor
subtype
Agonist afﬁnity 
MC1 MTII > NDP-a-MSH > a-MSH = ACTH-(1–24)  ACTH-(1–39) > b-MSH >>
MSH > RO27-3225
MC2 ACTH-(1–39) = ACTH-(1–24) 
MC3 MTII > NDP-a-MSH > [D-Trp8]g2-MSH > g1-MSH  g2-MSH = b-MSH = A
39) = ACTH-(1–24) > a-MSH
MC4 RO27–3225 > PG–931 > ME10501 > MTII ﬃ NDP-a-MSH >> a-MSH = ACT
39) = ACTH-(1–24) > b-MSH >> g1-MSH  g2-MSH
MC5 PG–911 > a-MSH = NDP-a-MSH = MTII  ACTH-(1–39) = ACTH-(1–24) = b
MSH  g2-MSH
The receptor afﬁnity of the main MC agonists is shown.Ohira, 2011; Suh et al., 2009; Vessal et al., 2007; Zhang and Chopp,
2009). Of note, brain insults stimulate endogenous neural
progenitor migration from the germinal zones to damaged areas,
where they can form mature neurons and glial cells, with potential
functional integration if the microenvironment is favourable.
Therapeutic strategies, designed to improve functional recovery
in neurodegenerative conditions, are under investigations. These
strategies mainly rely on pharmacologically-induced proliferation
of endogenous progenitors through an action on different cell
targets (Chohan et al., 2011; Giuliani et al., 2011; Irwin and Brinton,
2014; Lichtenwalner and Parent, 2006; Lie et al., 2004; Sun et al.,
2003; Suzuki et al., 2007; Wang et al., 2004). A potential target is
represented by primary cilia. Indeed, it is well established that
primary cilia  microtubule-based organelles  regulate neuronal
function in the developing and adult CNS and primary cilia
dysfunction causes complex human diseases (Louvi and Grove,
2011). Primary cilia are involved in modulation of signaling
pathways, including the canonical Wnt-3A/b-catenin and Sonic
hedgehog (Shh) pathways, whose persistent expression in adult
mammals play a key role in regulating neural stem/progenitor cell
proliferation and migration (Alvarez-Medina et al., 2009; Breunig
et al., 2008; Inestrosa and Arenas, 2010; Kuwabara et al., 2009; Lee
and Gleeson, 2010; Zhang et al., 2013). Many ion channels and
receptors, including melanocortin receptors, are expressed in the
membrane of primary cilia (Lee and Gleeson, 2010; Louvi and
Grove, 2011; Siljee-Wong et al., 2010). As stated above, primary
cilia are involved in the neurogenic process, therefore, could be
signiﬁcant targets. Another therapeutic strategy presently under
investigation is based on intracerebral transplantation or systemic
injection of a variety of cell types of both human and non-human
origin, including neural stem/progenitor cells from embryonic and
fetal tissue, gene-modiﬁed cells, immortalized neural cell lines,
multipotent cells such as hematopoietic/endothelial progenitors
and stromal cells from bone marrow, umbilical cord blood, and
adipose tissue (Burns et al., 2009; Glat and Offen, 2013; Lindvall
and Kokaia, 2010; Rodrigues et al., 2012; Vaquero and Zurita, 2011;
Zhang and Chopp, 2009). Albeit of great interest, cell-based
therapy appears very problematic (Hayes and Zavazava, 2013).
3. Melanocortins and their receptors
Melanocortins are endogenous peptides that occur in several
peripheral tissues and within the CNS. The melanocortin system
exerts modulation and homeostasis functions. These peptides act
through activation of ﬁve melanocortin G protein-linked, seven
transmembrane receptors (MC1 to MC5), all positively coupled
with adenylyl cyclase (Table 1) (Brzoska et al., 2008; Caruso et al.,
2014; Catania, 2007, 2008; Catania et al., 2004; Corander et al.,
2009; Diano, 2011; Getting, 2006; Giuliani et al., 2012; Lasaga et al.,
2008; Mountjoy, 2010; Mountjoy et al., 1992; Patel et al., 2010;ts.
Prevalent distribution of receptor
subtypes
 g1-MSH  g2- Melanocytes, hair follicles, glial cells, periaqueductal gray of the
midbrain, immune cells, endothelial cells, liver
Adrenal cortex; also detected in adipocytes, skin, testis and fetus
brain
CTH-(1– Brain, heart, kidney, gastrointestinal tract, immune cells
H-(1– Brain; expressed at low levels in some peripheral organs/tissues
-MSH >> g1- Widespread in many peripheral organs/tissues; detected in the
telencephalon of mammal embryo
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Entwistle, 1994; Versteeg et al., 1998; Wikberg et al., 2000;
Wikberg and Mutulis, 2008). The core sequence (6–9) shared by
natural melanocortins is required for binding to all MC receptors
(Catania et al., 2004; Oosterom et al., 1999; Getting, 2006; Schiöth,
2001). Although the transmembrane signaling primarily involves
activation of a cAMP-dependent pathway, melanocortin signaling
is also conveyed through additional, cAMP-independent pathways.
MC receptors are widely distributed within the CNS and in
peripheral tissues and, similar to other G protein-linked receptors,
they form dimeric or oligomeric complexes. The MC1 receptor is
expressed in melanocytes and other skin cells, hair follicles, testis,
kidney, periaqueductal gray of the midbrain, endothelial cells,
immune/inﬂammatory cells, and liver. MC2 is the ACTH receptor
and is mainly expressed in the adrenal glands, although it has also
been detected in adipocytes, skin, testis and fetus brain. MC3 is
expressed in the CNS, gut, kidney, heart, immune system, testis,
and skeletal muscle. MC4 has been mainly found in various brain
areas, although low expression levels are also found in the
periphery. The MC5 receptor is ubiquitous in peripheral organs
even if it has also been detected in the telencephalon of mammal
embryos. Despite their possible expression outside the brain, MC3
and MC4 are the predominant receptor subtypes in the CNS. MC4
expression is clearly broader than that of MC3, and recent evidence
indicates that MC4 receptors play a key protective role against
neuronal injury (Catania, 2008; Giuliani et al., 2010, 2012; Lasaga
et al., 2008; Mountjoy, 2010).
Melanocortins, modulate pathophysiological processes includ-
ing excitotoxicity, oxidative stress, inﬂammation and apoptosisTable 2
Preclinical studies on the protective effects of melanocortins in neurodegenerative diso
Preclinical condition Treatment Observed effects 
Transient global cerebral ischemia by bilateral
common carotid artery occlusion (gerbil, C57
BL/6 mouse)
a-MSH,
NDP-
a-MSH,
RO27-3225
# Hippocampal and 
inﬂammatory and ap
neurogenesis, Wnt-3
window; effects rev
Focal cerebral ischemia by intrastriatal
microinjection of endothelin-1 (rat)
NDP-
a-MSH
# Striatal damage, n
inﬂammatory and ap
time window; effect
vagotomy
Transient global cerebral ischemia by four vessel
occlusion (rat)
a-MSH # Astrocyte prolifera
Kainic acid-induced brain damage (rat) a-MSH # Excitotoxicity; " hi
Transient focal cerebral ischemia by unilateral
middle cerebral artery occlusion (mouse, rat)
a-MSH # Infarct size, cortica
sensory-motor orien
Transient brain stem ischemia by ventraspinal and
vertebral artery occlusion (dog)
a-MSH " Recovery of audito
Subarachnoid hemorrhage by injection of blood
into the cisterna magna (rat)
NDP-
a-MSH
Down-regulation of 
apoptosis, vascular r
Impact-acceleration model of traumatic brain
injury (rat)
NDP-
a-MSH
# Hippocampal and 
and apoptotic media
functional recovery, 
receptor blockade
Spinal cord injury by incision into the right dorsal
horn (rat)
ME10501 # Cell damage, cell l
receptors
Spinal cord injury by compression of the T10-T12
tract (mouse)
a-MSH # Histological damag
Alzheimer’s disease (APPSwe/PS1M146V/tauP301L
mouse)
NDP-
a-MSH
# Hippocampal and 
cascade, excitotoxic,
death; " Zif268 and 
receptor blockade
Alzheimer’s disease (Tg2576 mouse) NDP-
a-MSH
# Hippocampal and c
cognitive performan
receptor blockade
ERK 1/2: extracellular signal-regulated kinases 1/2; HMGB-1: High Mobility Group Box-1
NDP-a-MSH: [Nle4,D-Phe7]a-melanocyte-stimulating hormone; Shh: Sonic hedgehog; 
interleukin-6and contribute to protect the host from damage caused by
excessive reactions. An interesting and potentially relevant feature
is that melanocortins reduce, but do not abolish, local and systemic
inﬂammatory responses. Therefore they do not impair the defence
mechanisms in which a certain degree of inﬂammation is
beneﬁcial (Catania, 2007, 2008; Patel et al., 2010).
In view of their potential therapeutic use, synthesis of
melanocortin-related peptides and peptidomimetics as selective
agonists (Table 1) and antagonists at MC receptors is in progress. It
has been consistently reported that most of melanocortins and
their synthetic analogs reach the CNS in pharmacologically-
relevant concentrations after systemic injection, and experimental
evidence also supports this idea (Banks and Kastin, 1995; Benoit
et al., 2000; Catania, 2008; Corander et al., 2009; Giuliani et al.,
2006a, 2006b; Guarini et al., 1999, 2004; Holloway et al., 2011;
Mioni et al., 2005; Spaccapelo et al., 2011; Wikberg and Mutulis,
2008). Furthermore, permeability of the blood-brain barrier
signiﬁcantly increases in pathological conditions that cause brain
damage (Krizbai et al., 2005; Michalski et al., 2010; Sharma et al.,
2012), thus facilitating achievement of adequate brain concen-
trations of substances.
4. Melanocortins and ischemic stroke
4.1. Neuroprotective effects
Ischemic stroke is the leading cause of adult disability and the
second main cause of death in the United States and Europe (Lloyd-
Jones et al., 2009). Transient or prolonged severe decrease inrders.
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Activation of multiple pathological pathways within minutes to
days following the cerebrovascular accident are responsible for the
brain damage. Indeed, damage is caused by several mechanisms,
including excitotoxicity, inﬂammatory response, defective autoph-
agy, and apoptosis (Baldwin et al., 2010; Banerjee et al., 2010;
Dotson and Offner, 2017; Gladstone et al., 2002; Leker and
Shohami, 2002; Moskowitz et al., 2010; Zipp and Aktas, 2006). So
far, no novel drugs have established effectiveness in neuro-
protection, and the only approved therapy is thrombolysis within
3–4.5 h of symptom onset (Adams et al., 2007; Baldwin et al., 2010;
Ramee and White 2014; Yepes et al., 2009).
Neuroprotective properties of melanocortin agonists have been
demonstrated in several models of brain ischemia (Table 2). a-MSH
administration improved the recoveryof auditory-evoked potentials
in a dog model of transient brain stem ischemia (Huh et al.,1997) and
reduced brain inﬂammation in transient global and focal cerebral
ischemia in mice (Huang and Tatro, 2002). Recently, we provided the
ﬁrst evidence that short-term treatment (up to 11 days) with
nanomolar amounts of [Nle4,D-Phe7]a-MSH (NDP-a-MSH) and its
analog RO27-3225 induce a strong neuroprotection against damage
consequent to global or focal cerebral ischemia in gerbils and rats. Of
particular interest, the neuroprotective effect occurred also when
treatment was started several hours (up to 12–18) after ischemia
(Giuliani et al., 2006a, 2006b, 2007b, 2009; Ottani et al., 2009;
Spaccapelo et al., 2011). Forslin Aronsson et al., (2006) and Chen et al.
(2008) conﬁrmed the neuroprotective effect of a-MSH in other
models of global and focal cerebral ischemia in rats. The consistently
proved melanocortin-induced functional recovery after stroke
including improvement in learning, memory, sensory-motor orien-
tation, and limb coordination was accompanied by a treatment-
associated reduction in morphological damage with a greater
number of viable neurons (Chen et al., 2008; Forslin AronssonFig. 1. Schematic representation of pathways involved in the neuroprotective effects of
highlighted. Melanocortins induce both direct and indirect neuroprotection. Direct effect
apoptosis, and increase in synaptic plasticity) occur through the stimulation of MC
neuroprotection is consequent to the activation of the vagus nerve-mediated cholinergi
located in the vagus dorsal motor nucleus (DMN) and/or nucleus ambiguous (NA): this act
reticuloendothelial system (heart, liver, etc.). Acetylcholine released interacts with a7 su
immune cells, and counteracts damage mediator production, with a consequent inhibitio
of such peripheral pathological responses may result in cerebral protective signals and, co
signals from the periphery towards the CNS are likely conveyed, at least in part, via thet al., 2006; Giuliani et al., 2006a, 2006b, 2007b, 2009; Savos et al.,
2011; Spaccapelo et al., 2011).
A growing body of evidence indicates that the neuroprotective
effects of melanocortins occur through antagonism of excitotoxic,
inﬂammatory and apoptotic responses that are the main ischemia-
related mechanisms of damage (Table 2 and Fig. 1). Indeed, a-MSH
rescued neurons in a rat model of kainic acid-induced excitotox-
icity (Forslin Aronsson et al., 2007). Further, short-term treatment
of stroke animals with the melanocortins a-MSH, NDP-a-MSH,
and RO27-3225 reduced the brain level/activity of tumor necrosis
factor-a (TNF-a), interleukin-6 (IL-6), extracellular signal-regulat-
ed kinases (ERK), c-jun N-terminal kinases (JNK), p38 mitogen-
activated protein kinases (p38) and caspase-3, and increased
expression of the anti-apoptotic proteins Bcl-2 and Bcl-xL, with
consequent decrease in DNA fragmentation, which is the ultimate
feature of apoptosis (Huang and Tatro, 2002; Giuliani et al., 2006b;
Ottani et al., 2009; Spaccapelo et al., 2011).
The broad time-window of melanocortin treatment for a
successful neurological recovery, and the activity against the main
ischemia-related mechanisms of brain damage, originate a
potential, innovative neuroprotective approach.
4.2. Neurogenic effects
Data from our laboratory indicate that melanocortin treatment
causes long-lasting  or even deﬁnitive - functional recovery from
ischemic stroke associated with overexpression of the synaptic
activity-regulated gene Zif268 in the hippocampus (Giuliani et al.,
2006b, 2009). Zif268 is an early growth response gene involved in
injury repair. Together with other early growth response gene
family members it is rapidly induced as transcription factor by a
variety of physiological and pathological stimuli. The essential role
of Zif268 in synaptic plasticity, as well as in long-term survival, melanocortins in neurodegenerative diseases. Peripheral beneﬁcial effects are also
s (reduction of neuropathological hallmark lesions, excitotoxicity, inﬂammation and
4 receptors located in the central nervous system (CNS) injured area. Indirect
c anti-inﬂammatory pathway, through the stimulation of MC4 receptors seemingly
ivation promotes acetylcholine release from the efferent vagal ﬁbers in organs of the
bunit-containing nicotinic acetylcholine receptors on tissue macrophages and other
n of excitotoxic, inﬂammatory and apoptotic responses at peripheral level. Reduction
nsequently, reduced development of similar responses in the CNS. These protective
e afferent vagal ﬁbers, which are widely distributed throughout the CNS.
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been clearly demonstrated (Beckmann and Wilce, 1997; Giuliani
et al., 2009, 2011, 2014a; Veyrac et al., 2013). Melanocortins have
established neurotrophic effects, improve neural plasticity and are
involved in fetal development including CNS development
(Catania, 2008; Gispen et al., 1986; Simamura et al., 2011;
Starowicz and Przewłocka, 2003). Through stimulation of repair
mechanisms, including neurogenesis, melanocortins might like-
wise promote functional recovery after stroke.
Consistently, in a long-term study on stroke in gerbils we
recently found (Giuliani et al., 2011) that administration of NDP-
a-MSH for 11 days markedly increased the number of hippocam-
pus cells labeled with 5-bromo-20-deoxyuridine (BrdU). In these
experiments, BrdU, a thymidine analog that is incorporated into
DNA during cell division was injected intraperitoneally in gerbils
for 11 days to label proliferating cells. Confocal microscopy
examination on day 50 after stroke, showed that most of BrdU
immunoreactive cells were localized within the DG of NDP-
a-MSH-treated animals. In these experiments, almost all BrdU
positive cells expressed the mature neuronal marker NeuN, but not
the glial ﬁbrillary acidic protein (marker of astrocytes), indicating
that melanocortin treatment causes a shift toward the neuronal
phenotype. Furthermore, in NDP-a-MSH-treated stroke gerbils
almost all of BrdU-NeuN immunoreactive cells colocalized with
the early functional gene Zif268 (Table 2) (Giuliani et al., 2011).
This gene is primarily expressed after synaptic activation and is
used as an indicator of functionally integrated neurons (Becker
et al., 2007; Jessberger and Kempermann, 2003; Tashiro et al.,
2007).
With regard to the molecular mechanisms underlying mela-
nocortin-induced neurogenesis, recent ﬁndings from our labora-
tory indicate that treatment of stroke gerbils with NDP-a-MSH
produces DG over-expression of the principal regulators of neural
stem cell proliferation and fate determination (Table 2 and Fig. 2),Fig. 2. In neurodegenerative disorders melanocortins induce brain generation of new cel
representation of neurogenesis steps, and main mediators (Wnt-3A, b-catenin, Shh, Zif26
is up-regulated by MC4 receptor agonists; IL-1b (secreted by microglia) and BDNF (secr
down-regulated and up-regulated, respectively, by MC4 receptor agonists; IL-10 (secret
distant origin. Stimulation of the intact vagus nerve (not highlighted) also seems to i
subgranular zone; SVZ, subventricular zone; Shh, Sonic hedgehog; IL-10, interleukin-10;namely Wnt-3A/b-catenin and Sonic hedgehog (Shh), as well as
that of the early and immature neuronal marker doublecortin
(Giuliani et al., 2011; Spaccapelo et al., 2013). This effect was
observed over the early stage of neural stem/progenitor cell
development (days 1–10 after the ischemic insult). Consistent with
an essential role played by the Wnt-3A/b-catenin and Shh
pathways in the melanocortin-induced neurogenesis, gerbil
pretreatment with the Wnt-3A antagonist Dickkopf-1, or the
Shh antagonist cyclopamine, reduced the capacity of NDP-a-MSH
to induce neural stem/progenitor cell proliferation. Furthermore,
DG up-regulated expression of Zif268 was detected during the
early stage of neurogenesis. Notably, this gene plays an essential
role in synaptic plasticity, selection, maturation, and functional
integration of newborn neurons (Veyrac et al., 2013). Finally, high
levels of IL-10 were also detected in the DG, particularly in brain
vessels, thus suggesting a distant origin (Spaccapelo et al., 2013);
indeed, melanocortins induce production of the anti-inﬂammatory
cytokine IL-10 in peripheral blood monocytes and cultured
monocytes (Catania et al., 2004; Giuliani et al., 2012), and IL-10
is known to provide a favourable microenvironment for neuro-
genesis after ischemic stroke (Morita et al., 2007). Primary cilia
activity could be a target of melanocortins in the stimulation
process of neurogenesis. Primary cilia, in fact, modulate the Wnt-
3A/b-catenin and Shh signaling pathways (Alvarez-Medina et al.,
2009; Breunig et al., 2008; Inestrosa and Arenas, 2010; Kuwabara
et al., 2009; Lee and Gleeson, 2010), and melanocortin receptors
are expressed on the membrane of neuron primary cilia (Siljee-
Wong et al., 2010); however, an involvement of these organelles in
the melanocortin-induced neurogenesis has not yet been investi-
gated.
Induction of neuroprotection and neurogenesis with a broad
time-window, together with development of mature and func-
tional neuron properties by the newly generated cells, suggest an
interesting pharmacological proﬁle of melanocortins.ls that develop properties of mature and functionally integrated neurons. Schematic
8, DCX, NeuN) whose expression in neural stem/progenitor cells and newborn cells
eted by microglia and other brain mature cells such as neurons and astrocytes) are
ed by inﬂammatory cells, and up-regulated by MC4 receptor agonists) likely has a
nduce an increase in neural progenitor cell proliferation in adult mammals. SGZ,
 IL-1b, interleukin 1b; DCX, doublecortin; BDNF, brain-derived neurotrophic factor.
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5.1. Neuroprotective effects
Subarachnoid hemorrhage (SAH) is a type of hemorrhagic
stroke generally caused by the rupture of an aneurysm in a cerebral
artery that produces discharge of blood into the basal cisterns
(Citerio et al., 2007; Laskowitz and Kolls, 2010; Macdonald et al.,
2007). The most common and severe complication of SAH is a late
vasospasm. Approximately 50% of patients with symptomatic
vasospasm develop infarction, and 20% to 50% of these patients
experience a disabling stroke or die from progressive ischemia
(Lanterna et al., 2005; Laskowitz and Kolls, 2010; Macdonald et al.,
2007). Intracerebral hemorrhage is another type of hemorrhagic
stroke characterized by intraparenchimal hemorrhage. It can be
caused by a vessel rupture or it can occur as a complication of
thrombolytic treatment after ischemic stroke (Aronowski and Hall,
2005; Xi et al., 2006). Conventional drugs are used to maintain vital
functions, and various agents are being tested for prevention or
reduction of vasospasm, including magnesium sulfate, statins and
intra-arterial infusion of vasodilators. However, no consistently
efﬁcacious therapies have been implemented in clinical practice
(Moretti et al., 2015; Naggara and Nataf, 2013). Oxidative stress,
excitotoxicity, inﬂammatory response and apoptosis play a crucial
role in the pathogenesis of cerebral vasospasm after SAH. Data
indicate that the initial event after SAH is activation of genes
involved in angiogenesis, inﬂammation, and extracellular matrix
remodeling in cerebral arteries, that promote arterial contractility
(Cahill et al., 2006; Gatti et al., 2012; Maddahi et al., 2011; Vikman
et al., 2006). It appears, therefore, that correction of key steps of
this pathophysiological process may prevent vasoconstriction and
brain damage. Oxidative stress, excitotoxicity, inﬂammation and
apoptosis play a fundamental pathogenetic role also in intra-
parenchimal hemorrhage (Aronowski and Hall, 2005; Lee et al.,
2010).
The potential therapeutic effect of melanocortins in SAH has
been recently investigated in a rat model of the disorder (Table 2)
through evaluation of early gene expression proﬁling (at 4 h) and
delayed vasospasm (at day 5) in the basilar artery (Gatti et al.,
2012). In this study, NDP-a-MSH prevented SAH-induced alter-
ations of gene expression proﬁle in the basilar artery. In particular,
the peptide inhibited induction of genes involved in inﬂammation,
stress response, apoptosis and vascular remodelling, whereas it
enhanced expression of genes with a salutary role. Further, NDP-
a-MSH reduced vasospasm on day 5. The modulatory effect of
melanocortins on several detrimental pathways could account for
their potential beneﬁcial effects in these neurodegenerative
disorders.
A limited compensatory neurogenesis occurs after hemorrhagic
stroke, and the newly proliferating progenitors tend to migrate
from SVZ and SGZ to the site of injury (Masuda et al., 2007; Shen
et al., 2008). However, there are no data on a potential
melanocortin-induced ampliﬁcation of neurogenesis in these
conditions.
6. Melanocortins and traumatic injury of the CNS
6.1. Neuroprotective effects
Traumatic brain injury (TBI) and spinal cord injury (SCI) are
major and complex CNS disorders, frequently associated wih a
poor prognosis and lifelong neurological deﬁcits (Bragge et al.,
2012; Dumont et al., 2001; Gupta et al., 2010; Kumar and Loane,
2012; Leker and Shohami, 2002; Loane and Faden, 2010; Maegele
et al., 2007). In TBI, caused by direct head impact, injury is mostly
focal and results in cortical damage, vascular injury, andhemorrhage accompanied by ischemia; delayed diffuse brain
injury also includes axonal damage. Both the primary events and
the delayed secondary alterations contribute to neurological
deﬁcits. Similar to stroke, traumatic injury triggers an excitotoxic
and inﬂammatory response, and activation of an apoptotic
pathway. SCI primarily produces axonal disruption, vascular and
metabolic changes, followed by secondary extensive damage due
to excitotoxicity, inﬂammation and apoptosis. Furthermore, TBI is
an established risk factor for Alzheimers disease (Sivanandam and
Thakur, 2012). Methylprednisolone is the most prescribed agent in
SCI, and anticonvulsant drugs are generally recommended in TBI,
also because some of these products are thought to be neuro-
protective. Unfortunately, there is no clinically proven neuro-
protective therapy. Similar to stroke, the proposed new therapeutic
approaches for TBI and SCI failed for comparable reasons (Bragge
et al., 2012; Kabadi and Faden, 2014; Kumar and Loane, 2012; Loane
and Faden, 2010; Losiniecki and Shutter, 2010; Silva et al., 2014;
Xiong et al., 2009).
We recently found that delayed (up to 6 h) and short-term (up
to 7 days) treatment of TBI rats with the melanocortin analog NDP-
a-MSH produces marked protective effects (Table 2), including
modulation of the inﬂammatory response and inhibition of the
apoptotic cascade (Bitto et al., 2012). Remarkable observations
were reduced brain level/activity of nitrites, TNF-a, ERK, JNK, BAX
and caspase-3, and the increased expression of Bcl-2. Serum
concentrations of High Mobility Group Box-1 (HMGB-1) and IL-6
were decreased, whereas those of the anti-inﬂammatory cytokine
IL-10 were augmented. These changes resulted in a lesser degree of
brain damage in melanocortin-treated TBI animals with greater
number of viable neurons in the cortical region and in the
hippocampus and reduced axonal degeneration in the corpus
callosum. In these studies, biomolecular and morphological
improvement was distinctly correlated with functional recovery,
in particular with sensory-motor orientation and limb use
coordination, learning and memory (Bitto et al., 2012). The
therapeutic treatment window of melanocortins in TBI was
sufﬁciently broad, although shorter than that observed in stroke
conditions (Giuliani et al., 2006a, 2006b). Of note, the weight-drop
model used by Bitto et al. (2012) strengthens the value of this
study, because it allows to assess the therapeutic potential in TBI
conditions ranging from focal to diffuse brain injuries that
accurately reproduce potential clinical damage.
Neuroprotective effects of some low molecular weight non-
peptide compounds, with afﬁnity and activity at melanocortin
receptors, have been documented in a rat model of focal SCI
induced by incision into a right dorsal horn (Table 2) (Sharma et al.,
2006). Topical application of ME10501 to the spinal cord 5 min
after injury, markedly reduced cell damage, cell loss, sponginess
and edema at 5 h after injury. Further, in a mouse model of SCI
induced by compression of the T10-T12 spinal tract a-MSH
reduced histological damage and improved hind limb motor
function as assessed at day 14 after injury (Bharne et al., 2011).
Evidence indicates that reactive neurogenesis also occurs after
TBI and SCI, and newborn cells tend to migrate to the site of injury
(Bye et al., 2011; Vessal et al., 2007; Wiltrout et al., 2007; Xiong
et al., 2012; Zheng et al., 2013). Thus far, a possible melanocortin-
induced ampliﬁcation of neurogenesis in these neurodegenerative
conditions has not been studied.
7. Melanocortins and Alzheimer’s disease
7.1. Neuroprotective effects
AD is a chronic neurodegenerative disorder marked by severe
cognitive and behavioral deﬁcits. Sporadic AD is the most common
cause of dementia in the elderly, whereas the less prevalent form of
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(Galimberti et al., 2013; Iqbal and Grundke-Iqbal, 2010, 2011; Tayeb
et al., 2012). Typical features of AD brains are accumulation of
extra-cellular b-amyloid (Ab) ﬁbrillar deposits (Ab plaques), intra-
neuronal tau neuroﬁbrillary tangles (composed of hyperphos-
phorylated tau protein), and extensive neuronal loss in vulnerable
regions as the cortex and hippocampus (Blennow, 2010; Iqbal and
Grundke-Iqbal, 2010, 2011; Ittner and Götz, 2011; O’Bryant et al.,
2016; Sivanandam and Thakur, 2012; Sperling et al., 2013; Tayeb
et al., 2012). Evidence indicates that b-amyloid accumulation and
tau hyperphosphorylation trigger excitotoxic and inﬂammatory
responses that cause neurodegeneration and apoptotic cell death.
Glutamate, free radicals, cytokines, mitogen-activated protein
kinases and caspases play a signiﬁcant role in these detrimental
pathways (Bagheri et al., 2011; Friedlander, 2003; Giuliani et al.,
2013; Heneka et al., 2015; Tayeb et al., 2012; Sivanandam and
Thakur, 2012; Yuan and Yankner, 2000; Zhang et al., 2011; Zipp and
Aktas, 2006). Impaired cholinergic transmission and excessive
glutamate activity within the brain are hallmarks of the disorder.
Consequently, currently approved therapies for AD are mostly
based on cholinergic and anti-glutamatergic strategies, but this
approach generally induces transient and modest cognitive
improvement (Galimberti et al., 2013; Tayeb et al., 2012). In a
scenario in which there are no effective therapeutic solutions, new
effective pharmacological approaches are needed to at least retard
disease progression. Because disturbances occurring in AD patients
are multifaceted, cardiologists, ophthalmologists, and other
specialists should be involved in the therapeutic approach together
with neurologists (Cermakova et al., 2015; Ho et al., 2012; Schiöth
et al., 2012; Sivak, 2013).
Because of their potential beneﬁcial effects, melanocortins have
been the subject of several AD studies. A clinical investigation
reported low levels of ACTH/a-MSH in the cerebrospinal ﬂuid/
brain of patients with AD-related dementia (Arai et al., 1986;
Facchinetti et al., 1984; Rainero et al., 1988). In an in vitro model of
AD, a-MSH reduced production of inﬂammatory mediators by
cultured murine microglial cells stimulated with Ab (Galimberti
et al., 1999). Recent results from our laboratory showed that
melanocortins protect against progression of experimental AD
(Giuliani et al., 2014a). Indeed, in a triple-transgenic mouse model
of AD, which closely mimics human AD features (these mice harbor
human transgenes APPSwe, PS1M146V and tauP301L), daily treatment
with nanomolar doses of NDP-a-MSH (started at the age of 12
weeks and carried on until 30 weeks) signiﬁcantly reduced
cerebral cortex/hippocampus concentration/phosphorylation lev-
els of amyloid precursor protein, presenilin-1, Ab deposits, tau
(phosphorylated at sites Ser 202, Ser 396 and Thr 181),
malondialdeyde, nitrites, inﬂammatory and apoptotic mediators.
Relative to untreated controls, NDP-MSH-treated animals also
showed reduced neuronal loss, with over-expression of the
synaptic activity-dependent gene Zif268 and improvement in
cognitive functions. In another experimental model of AD
transgenic mice (APPSwe mice; Tg2576), NDP-a-MSH treatment
started at the age of 24 weeks and administered for 7 weeks
reduced cerebral cortex/hippocampus level of Ab deposit,
decreased neuronal loss, induced up-regulation of the activity-
dependent gene Zif268, and improved cognitive performance
(Giuliani et al., 2014b). Further, in TgCRND8 AD mice, a-MSH
treatment for 28 days (started at the age of 12 weeks) prevented
GABAergic neuronal loss and anxiety alterations, and improved
spatial memory (Ma and McLaurin, 2014). Collectively, these
ﬁndings indicate that melanocortins counteract the progression of
experimental AD by targeting pathophysiological pathways up-
and down-stream of Ab and tau, and through an improvement of
synaptic plasticity.7.2. Neurogenic effects
A very limited, if any, compensatory neurogenesis occurs in AD,
depending on age and disease severity (Becker et al., 2007; Ben
Menachem-Zidon et al., 2014; Iqbal and Grundke-Iqbal, 2011; Lilja
et al., 2013; Lo, 2010; Marlatt and Lucassen, 2010; Mu and Gage,
2011).
Encouraged by the impressive results obtained in stroke gerbils
(Giuliani et al., 2011), we recently investigated effects of
melanocortins in AD neurogenesis (Giuliani et al., 2015). We
found that a 50-day NDP-a-MSH treatment of Tg2576 mice with
moderate AD, not only preserved cerebral cortex and hippocampus
morphology and counteracted learning and memory decline, but
also induced an intense hippocampus DG proliferation of neural
stem/progenitor cells. Almost all BrdU positive cells counted on
day 50 of the study were also NeuN immunoreactive (but not GFAP
positive) and expressed Zif268, thus conﬁrming that melanocortin
treatment shifts cells toward a neuronal phenotype and promotes
functional integration of newborn neurons.
The mechanism underlying the neurogenic effect of melano-
cortins has not been investigated in AD, but it is reasonable to
hypothesize that the same molecular mechanisms identiﬁed in
stroke could lie behind the neurogenic effect of melanocortins in
AD animals. In particular, a melanocortin-induced up-regulation of
Wnt-3A/b-catenin, Shh, IL-10 and Zif268 (Giuliani et al., 2009,
2011, 2014a, 2014b) associated with down-regulation of IL-1b
signaling expression could have an eminent role (Giuliani et al.,
2014a). Indeed, these changes could promote over-expression of
neurogenesis facilitating factors, including brain-derived neuro-
trophic factor (BDNF) (Caruso et al., 2012, 2014). Both neurogenic
and neuroprotective effects depict an interesting pharmacological
proﬁle of melanocortins also in AD.
8. Involvement of MC4 receptors
As melanocortin MC4 receptors are the predominant melano-
cortin receptor subtype expressed in the CNS (Catania, 2008;
Getting, 2006; Giuliani et al., 2012; Mountjoy, 2010; Wikberg and
Mutulis, 2008), these receptors have been investigated in
neurodegenerative disorders (Table 2). Several investigations
determined effects of MC4 blockade on melanocortin effects.
Results showed that pretreatment with selective melanocortin
MC4 receptor antagonists prevent the neurogenic and/or neuro-
protective effect(s) induced by NDP-a-MSH (agonist at MC1, MC3,
MC4 and MC5 receptors) and RO27-3225 (selective agonist at MC4
receptors) in ischemic stroke, TBI and AD (Bitto et al., 2012;
Giuliani et al., 2006a, 2006b, 2007b, 2009, 2011, 2014a, 2014b,
2015; Spaccapelo et al., 2011, 2013). Furthermore, ME10501, a
compound that exerts a potent neuroprotective action in SCI, has
high afﬁnity and activity at MC4 receptors (Sharma et al., 2006).
Treatment of cerebral ischemia with the ACTH-(4–7) fragment
linked to its C terminal to the Pro-Gly-Pro sequence likewise been
induces neuroprotection (Dmitrieva et al., 2010; Stavchansky et al.,
2011), although an involvement of MC receptors in this effect has
not been reported. As a matter of fact, this compound does not bear
the common core sequence (6–9) of MSH, necessary for binding to
all MC receptor and for agonist activity (Brzoska et al., 2008;
Catania et al., 2004; Getting, 2006; Oosterom et al., 1999; Schiöth,
2001; Versteeg et al., 1998); thus it may be that the mechanism of
action of this molecule differs from that of melanocortin peptides.
Finally, the MC4 receptor agonist RY767 (a small non peptide
molecule) did not induce neuroprotection in a rat model of
ischemic stroke (Regan et al., 2009); however, this research only
assessed indirect infarct volume at day 3 after stroke, but
pathophysiological pathways, neuron viability and functional
recovery were not investigated.
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transduction of melanocortins inhibits neurodegeneration-related
key pathophysiological pathways. Consequently, repair mecha-
nisms could be favourably modulated by a physiologically based
self-defence machinery. Consistent with a signiﬁcant physiological
role played by MC4 receptors in neurodegeneration, enhanced
expression of MC4 receptors has been reported in brains of rats
subjected to ischemic stroke (Mountjoy et al., 1999). Further,
electrophysiological, immunocytochemical and biomolecular
studies have recently given evidence that MC4 receptors play a
crucial role in regulation of hippocampal synaptic plasticity (Shen
et al., 2013).
9. Melanocortins and associated peripheral effects of brain
injury
Systemic responses following brain injury have been charac-
terized, and there is evidence that modulation of systemic
responses could have cerebral protective effects (Fig. 1) (Anthony
et al., 2012; Catania et al., 2009; Mravec, 2010; Ottani et al., 2009).
Further, a bidirectional communication between the injured brain
and the peripheral immune system has been clearly documented
(An et al., 2014).
In recent research on a model of focal brain ischemia in rats, the
melanocortin peptide NDP-a-MSH suppressed the inﬂammatory
and apoptotic cascades and the excitotoxic reaction, not only in the
brain but also in peripheral tissues (Table 2) (Ottani et al., 2009).
Indeed, NDP-a-MSH inhibited JNK, ERK and caspase-3 activation,
as well as DNA fragmentation and TNF-a overexpression, in the
striatum, liver, and blood. These ﬁndings are consistent with the
established ability of melanocortins to reduce systemic inﬂamma-
tory responses in several conditions including circulatory shock
(Giuliani et al., 2010; Guarini et al., 2004). In TBI rats, increases in
circulating IL-6 and HMGB-1 (Bitto et al., 2012) could promote
systemic responses that, in turn, are detrimental to other organs
and their inhibition could, therefore, be beneﬁcial. In this regard, it
is of note that NDP-a-MSH blunted the TBI-induced systemic
release of HMGB-1 (Table 2) (Bitto et al., 2012), as this cytokine is a
key mediator of systemic inﬂammation, and a necessary and
sufﬁcient mediator for lethal inﬂammation (Tracey, 2007).
Overproduction of inﬂammatory mediators in chronic neuro-
degenerative disorders is associated with microglia activation and
chronic systemic inﬂammation may, in turn, accelerate the disease
progression (Cunningham, 2013). There is no direct information on
inﬂuences of melanocortins on peripheral alterations in other
neurodegenerative conditions, although it seems reasonable to
hypothesize that the beneﬁcial effects exerted in ischemic stroke
and TBI could likewise occur in hemorrhagic stroke, SCI and
possibly other, acute and chronic, neurodegenerative disorders.
10. Melanocortins and the vagus nerve against
neurodegeneration
Data suggest that the “cholinergic anti-inﬂammatory pathway”
could be involved in the protective effect of melanocortins against
neurodegeneration. The cholinergic anti-inﬂammatory pathway is
the effector arm of the “inﬂammatory reﬂex”, a self-defence
mechanism identiﬁed through studies on the local and systemic
inﬂammatory responses that follow circulatory shock, myocardial
ischemia and other diseases (Borovikova et al., 2000; Giuliani et al.,
2010, 2012; Guarini et al., 2003, 2004; Mioni et al., 2005; Tracey,
2002, 2007). The beneﬁcial effects induced by activation of this
pathway are mediated by the efferent vagal ﬁbers through
acetylcholine  the main vagus nerve neurotransmitter  and
peripheral a7 subunit-containing nicotinic acetylcholine recep-
tors. Effects consist of reduced expression of several pro-inﬂammatory cytokines, including IL-6, TNF-a and the late
mediator of severe inﬂammation HMGB-1 (Giuliani et al., 2010,
2012; Guarini et al., 2003; Rosas-Ballina et al., 2011; Tracey, 2002,
2007). Further, it appears that the vagus nerve exerts an
immunomodulatory function in the molecular communication
between the injured brain and the peripheral immune system (An
et al., 2014).
Recent investigations found that bilateral cervical vagotomy
and nicotinic receptor blockade with chlorisondamine prevent the
protective effects of melanocortins against brain and systemic
consequences of ischemic stroke (Ottani et al., 2009). Peripheral
inﬂammation associated with ischemic stroke, a signiﬁcant
component in both acute and long-term outcome, seems to be
favourably modulated by the vagus nerve. Reduction of peripheral
inﬂammation could consequently attenuate development of
systemic inﬂammation-induced neuroinﬂammation (Mravec,
2010; Ottani et al., 2009). Accordingly, in experimental intracere-
bral hemorrhage, activation of the cholinergic anti-inﬂammatory
pathway through intracerebroventricular injection of muscarinic
receptor agonists reduced the inﬂammatory responses in periph-
eral tissues and in the brain, with improvement in functional
recovery (Lee et al., 2010). A modulatory activity by the vagus nerve
has been likewise assumed in the melanocortin-induced decrease
in circulating IL-6 and HMGB-1 and in functional recovery in TBI
rats (Bitto et al., 2012). Similarly, electrical stimulation of the intact
vagus nerve reduced infarct size in rat focal cerebral ischemia,
presumably through activation of the cholinergic anti-inﬂamma-
tory pathway, and via an afferent vagal ﬁber-mediated modulation
of brain noradrenergic neuronal activity (Ay et al., 2009; Mravec,
2010). Interestingly, electrical stimulation of the intact vagus nerve
increased hippocampal progenitor cell proliferation in adult rats,
likely through a norepinephrine/serotonin-dependent mechanism
(Revesz et al., 2008). The effect of vagus stimulation on cognition
and memory remains controversial. However, in pilot studies,
stimulation of the intact vagus nerve improved cognitive functions
in AD patients, likely as a consequence of synaptic activation at
multiple brain sites; therefore, a potential therapeutic use is under
investigation (Iturri Clavero et al., 2010; Vonck et al., 2014). Finally,
a7 nicotinic receptor agonists have been reported to promote
neuronal differentiation of neural stem/progenitor cells in mice
(Narla et al., 2013).
These ﬁndings indicate that vagal afferent and efferent path-
ways could be involved in the modulation of peripheral and central
inﬂammation, neuronal plasticity and perhaps compensatory
neurogenesis in neurodegenerative conditions. Notably, seminal
observations on the signiﬁcant role played by the vagus nerve and
acetylcholine in the anti-shock effects of melanocortins were
reported about thirty years ago (Guarini et al., 1986). In subsequent
research on experimental hemorrhagic shock and myocardial
ischemia, melanocortins were found to stimulate the motor arm of
the inﬂammatory reﬂex. Namely, the vagus nerve-mediated
cholinergic anti-inﬂammatory pathway was activated through
stimulation of brain MC3/MC4 receptors located in the vagus dorsal
motor nucleus and/or nucleus ambiguus (Giuliani et al., 2010,
2012; Guarini et al., 2004; Mioni et al., 2005). The effect of
melanocortins on the sensory arm (afferent vagal ﬁbers) has not
been directly investigated; however, pretreatment with capsaicin
— which induces desensitization of certain sub-populations of
primary afferent nerve ﬁbers, including vagal ﬁbers — prevented
the anti-shock effect of ACTH-(1–24) in the rat (Guarini et al.,
1992). Collectively, these ﬁndings suggest that endogenous
melanocortin neuropeptides could be physiologically involved in
neuroprotection and in neurogenesis, and in protection against the
systemic effects of a brain injury. This effect could occur not only
via a direct protective effect within the CNS but also through
activation of the vagus nerve (Fig. 1). Of note, the dorsal vagal
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area postrema and dorsal motor nucleus of the vagus nerve lacks
the blood-brain barrier (Tracey, 2002), thus this brain region can be
easily reached by systemically administered molecules including
melanocortin peptides.
11. Potential therapeutic use
Evidence from prolonged preclinical studies, with observation
times up to two months after brain injury, suggests that both
neuroprotection and ampliﬁcation of reactive neurogenesis could
contribute to a long-lasting melanocortin-induced functional
recovery in different types of acute brain insults, including focal
and global cerebral ischemia, SAH, TBI and SCI (Bitto et al., 2012;
Chen et al., 2008; Forslin Aronsson et al., 2006; Gatti et al., 2012;
Giuliani et al., 2006a, 2006b, 2007b, 2011; Savos et al., 2011;
Sharma et al., 2006) (Fig. 3). Based on experimental evidence in
these conditions, the potential therapeutic use of melanocortins
could be conceptually extended to include intracerebral hemor-
rhage. Additional disorders, such as those characterized by brain
injury caused by carotid damage, could likewise beneﬁt from
melanocortin treatment. However, appropriate studies using
speciﬁc experimental models (Guarini, 1996) should be carried
out. The broad therapeutic treatment window of melanocortins is
remarkable and represents a key component together with the low
doses required (nanomolar amounts/daily) and the short treat-
ment duration (approximately up to 1–2 weeks) required for a
successful approach to acute neurodegenerative conditions.
Moreover, recent data suggest that chronic treatment (up to 7–
18 weeks) with nanomolar doses of melanocortins could counter-
act AD progression (Giuliani et al., 2014a, 2014b, 2015) in the
absence of harmful side effects. Indeed, the absence of toxicity is aFig. 3. Potential therapeutic uses of melanocortins in neurodegenerative diseases. Left: su
extension to other neurodegenerative disorders. SAH: subarachnoid hemorrhage; ICH: consistent melanocortin characteristic that has been dependably
pointed out also in protracted treatments and in different
pathological conditions (Brzoska et al., 2008; Catania et al.,
2004; Giuliani et al., 2012; Minutoli et al., 2011a; Wikberg and
Mutulis, 2008). Therefore, when considering the potential
therapeutic use of melanocortins, in AD, a chronic disorder
marked by neurological symptoms associated with impairment
of several other organs and systems, this favourable feature should
be included.
Endogenous melanocortins exert modulatory functions, and
several data support the idea that these peptides may play a
physiological, protective role against different types of brain
injuries, including ischemic stroke, SAH, TBI, SCI and AD. Indeed,
clinical investigations reported that a-MSH plasma levels are
decreased in patients with ischemic stroke, SAH and TBI with an
unfavourable outcome (Magnoni et al., 2003; Zierath et al., 2011).
In addition, low ACTH/a-MSH levels were found, in sporadic
studies, in the cerebrospinal ﬂuid and certain brain areas of AD-
type dementia patients (Arai et al., 1986; Facchinetti et al., 1984),
and in the cerebrospinal ﬂuid of patients with late onset of AD-type
dementia (Rainero et al., 1988). Further, melanocortins have
established ability to induce neurotrophic effects on central
cholinergic neurons, and for this reason many years ago it was
hypothesized that a-MSH deﬁciency could be cause of AD
(Anderson, 1986). It is relevant in this regard the observation that
melanocortins increase serum levels of the anti-inﬂammatory
cytokine IL-10 in TBI animals (Bitto et al., 2012). Such effect could
indeed contribute to reduction of the inﬂammatory responses in
such conditions, as low plasma concentrations of IL-10 are
associated with early worsening of neurological symptoms in
patients with acute stroke (Vila et al., 2003). Further, evidence for a
role of IL-10 in the regulation of the systemic inﬂammatoryggestion based on results in preclinical studies; right: proposal based on conceptual
intracerebral hemorrhage.
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2004). It appears that IL-10 is required in CD4+ T cells-mediated
neuroprotection (Xin et al., 2011). Finally, the established ability of
melanocortins to activate the vagus nerve could play a key
protective role not only in acute, but also in chronic neurodegen-
erative disorders, such as AD, in which vagus nerve stimulation is
under investigation as a potential therapeutic strategy (Iturri
Clavero et al., 2010).
Therefore, the proven ability of melanocortins to act at brain
MC4 receptors to prevent injury by targeting multiple pathways in
acute and chronic experimental neurodegeneration strongly needs
well-constructed randomized controlled trial/blinded studies to
cross from pre-clinical into clinical arena. Indeed, the capacity of
MC4 activation to promote tissue repair and functional recovery
within the brain, suggests encouraging perspectives on the clinical
use of MC4 agonists.
12. Potential developments to treat other neurodegenerative
disorders
Triggers and pathological biomarkers of neurodegenerative
diseases are quite different. This wide spectrum includes ischemia,
trauma, subarachnoid and intracerebral hemorrhage, plaques and
tangles, Lewy bodies, motoneuron death, nerve demyelination,
huntingtin protein accumulation, and more. Nevertheless, as
stated above, multiple convergent pathophysiological pathways
leading to neuronal death are activated in both acute and chronic
neurodegenerative diseases (Adwan and Zawia, 2013; Antel et al.,
2012; Banerjee et al., 2010; Drouin-Ouellet and Cicchetti, 2012;
Dumont et al., 2001; Kumar and Loane, 2012; Friedlander, 2003;
Gao et al., 2012; Glass et al., 2010; Haass, 2010; Heneka et al., 2015;
Iqbal and Grundke-Iqbal, 2010, 2011; Jakovcevski and Akbarian,
2012; Karbowski and Neutzner, 2012; Leker and Shohami, 2002;
Leuner et al., 2012; Lo, 2010; Loane and Faden, 2010; Moskowitz
et al., 2010; Sofroniew, 2015; Walsh et al., 2014; Yuan and Yankner,
2000; Zhang et al., 2011; Zipp and Aktas, 2006). Treatments
targeting these common pathways could have a broader use in
neurodegenerative diseases. Melanocortins meet this criterion
and, therefore, they deserve further investigation.
As stated above, melanocortins may play a physiological
protective role in several acute and chronic neurodegenerative
disorders (Fig. 3), and melanocortin treatment could induce not
only neuroprotection but also neurogenesis. For example, acute
episodes of severe hypoxia, which are among the most common
stressors in newborn children, can lead to neurodegeneration
(Florio et al., 2010). Melanocortins could provide neuroprotection
in these neonates. Consistent with this idea, hypoxia increases
plasma levels of ACTH and ACTH precursors in the near-term ovine
fetus, and shifts towards an ACTH-dependent physiological
response in the neonatal rat (Bruder et al., 2008; Myers et al.,
2005). Brain damage can also occur in acute carbon monoxide
poisoning (Busl and Greer, 2010), and reactive increases in
circulating ACTH were observed in patients with acute carbon
monoxide poisoning (Raff et al., 1985), thus supporting a possible
neuroprotective effect of melanocortins. Increased cerebrospinal
levels of melanocortins have been found in patients with
Parkinson’s disease; such increase has been interpreted as a
neuromelanin-mediated compensatory mechanism for protection
of neural components of the substantia nigra (Halabe Bucay, 2008).
Conversely, low plasma concentrations of a-MSH were found
during exacerbation phases of multiple sclerosis (Sandyk and
Awerbuch, 1992). It is well known that astrocyte products
contribute to neuroprotection. This is particularly interesting as
MC4 receptor activation induces expression of BDNF in rat
astrocytes (Caruso et al., 2012). This factor was found to be
neuroprotective in experimental models of AD, Parkinson’sdisease, amyotrophic lateral sclerosis, and Huntington’s disease
(Nagahara and Tuszynski, 2011). Multiple sclerosis patients have
decreased plasma concentrations of BDNF relative to healthy
controls, but levels increased after clinical recovery from a
relapsing phase (Frota et al., 2009); this observation is consistent
with a neuroprotective role for this neurotrophin also in this
disease.
Width of treatment time window is crucial in acute disorders
such as stroke or TBI, and evidence indicates that the protective
effects of melanocortins occur also when treatment is started
several hours after the insult (Bitto et al., 2012; Giuliani et al.,
2006a, 2006b, 2009; Spaccapelo et al., 2011). It is reasonable to
hypothesize that timeliness is also essential for treatment of
chronic neurodegenerative diseases, such as Alzheimer, Parkinson,
amyotrophic lateral sclerosis, or multiple sclerosis. It appears
obvious that neuronal dysfunction is more easily controlled by
pharmacological stimulation of endogenous mechanisms of
compensation, remodelling and repair in the initial phases of
the disorder, when patients are still asymptomatic. As disease
severity advances, stimulation of endogenous protective mecha-
nisms, both neuroprotective and neurogenic, would likely be less
effective. It is worth noting that the majority of studies on
experimental chronic neurodegenerative diseases are based on
early disease stage, whereas patients usually start therapy when
the disease has already reached advanced severity. Therefore,
investigations in aged animals and in a late stage of chronic
neurodegenerative disorders should be encouraged to assess the
potential beneﬁcial effects of melanocortins.
13. Conclusions
The proved ability of melanocortins to modulate, with a broad
time window, central and peripheral pathophysiological responses
to different types of brain injury establishes a strong pharmaco-
logical framework for a potentially successful use of these
molecules in treatment of neurodegenerative disorders. Up-
regulation of the Zif268 gene, which is essential for synaptic
transmission and plasticity and is involved in many processes
related to injury repair, induction of new cells that develop
properties of mature and functional neurons in the injured brain
areas, and improvement of neurocognitive and motor perfor-
mance, support this idea.
Interestingly, melanocortins induce phenotype changes both in
the heart and in the brain that resemble ischemic preconditioning
(Catania et al., 2010; Gatti et al., 2012). Therefore, the precondi-
tioning-like effect could further contribute to neuroprotection in
brain injury. Consistently, preconditioning and postconditioning as
innovative strategies against ischemia/reperfusion injury of
several organs including the brain — and against other CNS insults
— are under investigation, with encouraging results (Granfeldt
et al., 2009; Stetler et al., 2014; Veighey and Macallister, 2012).
Moreover, the antipyretic action of melanocortins is well
established, and melanocortin-induced hypothermia can likewise
contribute to neuroprotection against acute neurodegeneration
(Holloway et al., 2011; Spulber et al., 2005; Tatro, 2006; Tatro and
Sinha, 2003). Experimental and clinical studies provide increasing
evidence that therapeutic hypothermia could be useful in several
brain injuries (Marion and Bullock, 2009; Maybhate et al., 2012;
Moore et al., 2011; Salerian and Saleri, 2008; Yenari and Han, 2012).
Indeed, hypothermia decreases blood ﬂow and metabolism, and
preserves blood-brain barrier. Further, it blunts the cascade of
detrimental processes that occur after a brain injury, such as
excitotoxicity, free radical discharge, inﬂammation and apoptosis.
It has been suggested that chronic cooler core body temperatures
may prolong longevity and retard neurodegeneration.
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angiogenesis.
The melanocortin system is thought to be activated in
inﬂammatory or stress conditions where it likely contributes to
resolution of inﬂammation. It may be that chronic inﬂammation
results from ineffective engagement of these physiological
peptides including their receptors (Ahmed et al., 2014). It is worth
considering that melanocortins are modulators of several patho-
physiological processes that contribute to protect the host from
damage caused by excessive reactions: indeed melanocortins
reduce, but not abolish, local and systemic inﬂammatory
responses, and therefore they do not impair the defence
mechanisms (Catania, 2007, 2008; Catania et al., 2004, 2006;
Patel et al., 2010). Further, these peptides do not reduce microbial
killing activity of neutrophils but they rather enhance it, and exert
direct broad-spectrum antimicrobial effect (Catania et al., 2009;
Grieco et al., 2013). This peculiar characteristic could be of great
relevance for treating neurodegenerative conditions in immuno-
compromised patients, e.g., patients with ischemic stroke, TBI, SAH
(where infections are a prominent cause of death), and in AD
(where old age-induced vulnerability to infectious agents may
contribute to the onset and progression of the disease) (Catania
et al., 2009; Kourbeti et al., 2012; Sy et al., 2011; Westendorp et al.,
2011).
Finally, it is important to underscore that all the melanocortin
effects described in this review are independent from adrenal
steroid production: indeed, the melanocortin peptides used in the
cited experiments (a-MSH, NDP-a-MSH, RO27-3225, ME10501)
do not bind MC2 receptors, expressed in adrenal cortex and
required for glucocorticoid release and, therefore, are devoid of
corticotropic activity (Benoit et al., 2000; Catania et al., 2004;
Corander et al., 2009; Giuliani et al., 2010, 2012; Patel et al., 2010;
Wikberg and Mutulis, 2008). Thus, adverse effects associated with
glucocorticoid increases would be avoided. Notably, certain
melanocortin compounds have already been tested in clinical
trials for treatment of weight disorders, sexual dysfunction and
skin diseases, with no toxicity problem (for reviews see: Brzoska
et al., 2008; Caruso et al., 2014; Corander et al., 2009; Wikberg and
Mutulis, 2008). However, in normal animals, some melanocortins
(e.g., g1-MSH, g2-MSH) increase blood pressure and heart rate after
intravenous administration, whereas ACTH-(1–24), a-MSH and
analogs lacking the C-terminal Arg-Phe sequence do not cause
blood pressure increase in normal animals; interestingly, ACTH-
(1–24) is able to decrease arterial blood pressure and to increase
heart rate (Mioni et al., 2003). This solid clinical experience should
be very helpful for implementation of therapeutic use of
melanocortins in neurodegeneration.
Clinical advantages of melanocortin treatment after a brain
injury include the approach easiness, not only for neuroprotection
but also for brain regeneration. This would be a signiﬁcant
difference relative to the novel and controversial, stem cell-based
approaches presently under investigation. Indeed, such therapies
not only require demonstration of efﬁcacy and cell survival, but
they also need a strategy to control cell proliferation and safety
(Burns et al., 2009; Hayes and Zavazava, 2013; Vaquero and Zurita,
2011). Therefore, scientists, clinicians, regulators and ethicists
should deeply collaborate for a responsible clinical translation of
such approaches. A potential limitation linked to treatment of
neurodegenerative conditions with natural melanocortins could
be the fast breaking down of these peptides in the body ﬂuids
although several of the generated fragments are biologically active
(Brzoska et al., 2008; Catania et al., 2004). Another potential
problem of the natural peptides is the lack of selectivity at
melanocortin receptors, and, consequently, a broad activity on
central and peripheral tissues and functions (Brzoska et al., 2008;
Catania et al., 2004; Corander et al., 2009; Getting, 2006; Schiöth,2001; Vergoni and Bertolini, 2000; Wikberg and Mutulis, 2008).
Therefore, stable and highly selective agonists at MC4 receptor are
needed to cure neurodegenerative disorders. Finally, it should be
considered that the neurogenic effect of melanocortins has been
investigated and proved so far only in an experimental model of
ischemic stroke and AD; thus the observation needs to be extended
to other conditions.
In conclusion, the exciting results so far obtained encourage
melanocortin studies in various experimental models that reﬂect
the other human neurodegenerative diseases. These investigations
could constitute an important challenge for the development of
innovative drugs, with both neuroprotective and neurogenic
properties, against acute and chronic neurodegenerative disorders.
Parallel efforts should be devoted to design of synthetic peptides
with potentially improved pharmacological proﬁle.
Disclosure
Prof. . Giuliani and Prof. Guarini are inventors on a patent
(owner University of Modena and Reggio Emilia) related to the
topic of the present paper. The other authors have no disclosure to
declare related to this topic.
Acknowledgments
Work performed in authors’ laboratory, relevant to the topic
discussed in this review, was supported in part by grants from
Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR),
Roma, and University of Modena and Reggio Emilia, Italy. Reprint
cost of the present review was supported by grants from
Fondazione Cassa di Risparmio di Modena, Italy. We thank Dr.
Fabrizio Canalini and Dr. Anita Calevro for excellent editorial
assistance.
References
Adams, H.P., Del Zoppo, G., Alberts, M.J., Bhatt, D.L., Brass, L., Furlan, A., Grubb, R.L.,
Higashida, R.T., Jauch, E.C., Kidwell, C., Lyden, P.D., Morgenstern, L.B., Qureshi, A.
I., Rosenwasser, R.H., Scott, P.A., Wijdicks, E.F., 2007. Guidelines for the early
management of adults with ischemic stroke. Stroke 38, 1655–1711.
Adwan, L., Zawia, N.H., 2013. Epigenetics: a novel therapeutic approach for the
treatment of Alzheimer's disease. Pharmacol. Ther. 139, 41–50.
Ahmed, T.J., Kaneva, M.K., Pitzalis, C., Cooper, D., Perretti, M., 2014. Resolution of
inﬂammation: examples of peptidergic players and pathways. Drug Discov.
Today 19, 1166–1171.
Altavilla, D., Cainazzo, M.M., Squadrito, F., Guarini, S., Bertolini, A., Bazzani, C., 1998.
Tumour necrosis factor-a as a target of melanocortins in haemorrhagic shock, in
the anaesthetized rat. Br. J. Pharmacol. 124, 1587–1590.
Alvarez-Medina, R., Le Dreau, G., Ros, M., Martí, E., 2009. Hedgehog activation is
required upstream of Wnt signalling to control neural progenitor proliferation.
Development 136, 3301–3309.
An, C., Shi, Y., Li, P., Hu, X., Gan, Y., Stetler, R.A., Leak, R.K., Gao, Y., Sun, B.L., Zheng, P.,
Chen, J., 2014. Molecular dialogs between the ischemic brain and the peripheral
immune system: dualistic roles in injury and repair. Prog. Neurobiol. 115, 6–24.
Anderson, B., 1986. Is alpha-MSH deﬁciency the cause of Alzheimer's disease? Med.
Hypotheses 19, 379–385.
Antel, J., Antel, S., Caramanos, Z., Arnold, D.L., Kuhlmann, T., 2012. Primary
progressive multiple sclerosis: part of the MS disease spectrum or separate
disease entity? Acta Neuropathol. 123, 627–638.
Anthony, D.C., Couch, Y., Losey, P., Evans, M.C., 2012. The systemic response to brain
injury and disease. Brain Behav. Immun. 26, 534–540.
Arai, H., Moroji, T., Kosaka, K., Iizuka, R., 1986. Extrahypophyseal distribution of
a-melanocyte stimulating hormone (a-MSH)-like immunoreactivity in
postmortem brains from normal subjects and Alzheimer-type dementia
patients. Brain Res. 377, 305–310.
Aronowski, J., Hall, C.E., 2005. New horizons for primary intracerebral hemorrhage
treatment: experience from preclinical studies. Neurol. Res. 27, 268–279.
Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., Lindvall, O., 2002. Neuronal replacement
from endogenous precursors in the adult brain after stroke. Nat. Med. 8, 963–
970.
Ay, I., Lu, J., Ay, H., Gregory Sorensen, A., 2009. Vagus nerve stimulation reduces
infarct size in rat focal cerebral ischemia. Neurosci. Lett. 459, 147–151.
Bagheri, M., Joghataei, M.T., Mohseni, S., Roghani, M., 2011. Genistein ameliorates
learning and memory deﬁcits in amyloid b(1–40) rat model of Alzheimer's
disease. Neurobiol. Learn. Mem. 95, 270–276.
52 D. Giuliani et al. / Progress in Neurobiology 148 (2017) 40–56Baldwin, K., Orr, S., Briand, M., Piazza, C., Veydt, A., McCoy, S., 2010. Acute ischemic
stroke update. Pharmacotherapy 30, 493–514.
Banerjee, R., Beal, M.F., Thomas, B., 2010. Autophagy in neurodegenerative
disorders: pathogenetic roles and therapeutic implications. Trends Neurosci.
33, 541–549.
Banks, W.A., Kastin, A.J., 1995. Permeability of the blood-brain barrier to
melanocortins. Peptides 16, 1157–1161.
Bazzani, C., Guarini, S., Botticelli, A.R., Zaffe, D., Tomasi, A., Bini, A., Cainazzo, M.M.,
Ferrazza, G., Mioni, C., Bertolini, A., 2001. Protective effect of melanocortin
peptides in rat myocardial ischemia. J. Pharmacol. Exp. Ther. 297, 1082–1087.
Bazzani, C., Mioni, C., Ferrazza, G., Cainazzo, M.M., Bertolini, A., Guarini, S., 2002.
Involvement of the central nervous system in the protective effect of
melanocortins in myocardial ischaemia/reperfusion injury. Resuscitation 52,
109–115.
Becker, M., Lavie, V., Solomon, B., 2007. Stimulation of endogenous neurogenesis by
anti-EFRH immunization in a transgenic mouse model of Alzheimer’s disease.
Proc. Natl. Acad. Sci. U. S. A. 104, 1691–1696.
Beckmann, A.M., Wilce, P.A., 1997. Egr transcription factors in the nervous system.
Neurochem. Int. 31, 447–510.
Ben Menachem-Zidon, O., Menahem, Y.B., Hur, T.B., Yirmiya, R., 2014. Intra-
hippocampal transplantation of neural precursor cells with transgenic over-
expression of IL-1 receptor antagonist rescues memory and neurogenesis
impairments in an Alzheimer's disease model. Neuropsychopharmacology 39,
401–414.
Benarroch, E.E., 2013. Adult neurogenesis in the dentate gyrus: general concepts and
potential implications. Neurology 81, 1443–1452.
Benoit, S.C., Schwartz, M.W., Lachey, J.L., Hagan, M.M., Rushing, P.A., Blake, K.A.,
Yagaloff, K.A., Kurylko, G., Franco, L., Danhoo, W., Seeley, R.J., 2000. A novel
selective melanocortin-4 receptor agonist reduces food intake in rats and mice
without producing aversive consequences. J. Neurosci. 20, 3442–3448.
Bertolini, A., Vergoni, W., Gessa, G.L., Ferrari, W., 1969. Induction of sexual
excitement by the action of adrenocorticotrophic hormone in brain. Nature 221,
667–669.
Bertolini, A., Poggioli, R., Vergoni, A.V., Castelli, M., Guarini, S., 1986. Evidence that
melanocortins are physiological antagonist of opioids. In: De Wied, D., Ferrari,
W. (Eds.), Central Actions of ACTH and Related Peptides. Springer-Verlag, Berlin-
Heidelberg, pp. 207–222.
Bertolini, A., Ferrari, W., Guarini, S.,1989. The adrenocorticotropic hormone (ACTH)-
induced reversal of hemorrhagic shock. Resuscitation 18, 253–267.
Bertolini, A., 1995. The opioid/anti-opioid balance in shock: a new target for therapy
in resuscitation. Resuscitation 30, 29–42.
Bharne, A.P., Upadhya, M.A., Kokare, D.M., Subhedar, N.K., 2011. Effect of alpha-
melanocyte stimulating hormone on locomotor recovery following spinal cord
injury in mice: role of serotonergic system. Neuropeptides 45, 25–31.
Bitto, A., Polito, F., Irrera, N., Calò, M., Spaccapelo, L., Marini, H.R., Giuliani, D., Ottani,
A., Rinaldi, M., Minutoli, L., Guarini, S., Squadrito, F., Altavilla, D., 2012. Protective
effects of melanocortins on short-term changes in a rat model of traumatic
brain injury. Crit. Care Med. 40, 945–951.
Blennow, K., 2010. Biomarkers in Alzheimer’s disease drug development. Nat. Med.
16, 1218–1222.
Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I., Watkins, L.R., Wang,
H., Abumrad, N., Eaton, J.W., Tracey, K.J., 2000. Vagus nerve stimulation
attenuates the systemic inﬂammatory response to endotoxin. Nature 405, 458–
462.
Bragge, P., Chau, M., Pitt, V.J., Bayley, M., Eng, J.J., Teasell, R., Wolfe, D.L., Gruen, R.L.,
2012. An overview of published research about the acute care and rehabilitation
of traumatic brain injured and spinal cord injured patients. J. Neurotrauma 29,
1539–1547.
Breunig, J.J., Sarkisian, M.R., Arellano, J.I., Morozov, Y.M., Ayoub, A.E., Sojitra, S.,
Wang, B., Flavell, R.A., Rakic, P., Town, T., 2008. Primary cilia regulate
hippocampal neurogenesis by mediating sonic hedgehog signaling. Proc. Natl.
Acad. Sci. U. S. A. 105, 13127–13132.
Bruder, E.D., Taylor, J.K., Kamer, K.J., Raff, H., 2008. Development of the ACTH and
corticosterone response to acute hypoxia in the neonatal rat. Am. J. Physiol.
Regul. Integr. Comp. Physiol. 295, 1195–1203.
Brzoska, T., Luger, T.A., Maaser, C., Abels, C., Böhm, M., 2008. a-Melanocyte-
stimulating hormone and related tripeptides: biochemistry, antiinﬂammatory
and protective effects in Vitro and in Vivo, and future perspectives for the
treatment of immune-mediated inﬂammatory diseases. Endocr. Rev. 29, 581–
602.
Burns, T.C., Verfaillie, C.M., Low, W.C., 2009. Stem cells for ischemic brain injury: a
critical review. J. Comp. Neurol. 515, 125–144.
Busl, K.M., Greer, D.M., 2010. Hypoxic-ischemic brain injury: pathophysiology,
neuropathology and mechanisms. NeuroRehabilitation 26, 5–13.
Bye, N., Carron, S., Han, X., Agyapomaa, D., Ng, S.Y., Yan, E., Rosenfeld, J.V., Morganti-
Kossmann, M.C., 2011. Neurogenesis and glial proliferation are stimulated
following diffuse traumatic brain injury in adult rats. J. Neurosci. Res. 89, 986–
1000.
Cahill, J., Calvert, J.W., Zhang, J.H., 2006. Mechanisms of early brain injury after
subarachnoid hemorrhage. J. Cereb. Blood Flow. Metab. 26, 1341–1353.
Caruso, C., Carniglia, L., Durand, D., Gonzalez, P.V., Scimonelli, T.N., Lasaga, M., 2012.
Melanocortin 4 receptor activation induces brain-derived neurotrophic factor
expression in rat astrocytes through cyclic AMP-protein kinase A pathway. Mol.
Cell. Endocrinol. 348, 47–54.Caruso, V., Lagerström, M.C., Olszewski, P.K., Fredriksson, R., Schiöth, H.B., 2014.
Synaptic changes induced by melanocortin signalling. Nat. Rev. Neurosci. 15,
98–110.
Catania, A., Gatti, S., Colombo, G., Lipton, J.M., 2004. Targeting melanocortin
receptors as a novel strategy to control inﬂammation. Pharmacol. Rev. 56, 1–29.
Catania, A., Colombo, G., Rossi, C., Carlin, A., Sordi, A., Lonati, C., Turcatti, F., Leonardi,
P., Grieco, P., Gatti, S., 2006. Antimicrobial properties of a-MSH and related
synthetic melanocortins. Sci. World J. 6, 1241–1246.
Catania, A., Lonati, C., Sordi, A., Gatti, S., 2009. Detrimental consequences of brain
injury on peripheral cells. Brain Behav. Immun. 23, 877–884.
Catania, A., Lonati, C., Sordi, A., Leonardi, P., Carlin, A., Gatti, S., 2010. The peptide
NDP-MSH induces phenotype changes in the heart that resemble ischemic
preconditioning. Peptides 31, 116–122.
Catania, A., 2007. The melanocortin system in leukocyte biology. J. Leukoc. Biol. 81,
383–392.
Catania, A., 2008. Neuroprotective action of melanocortins: a therapeutic
opportunity. Trends Neurosci. 31, 353–360.
Cermakova, P., Eriksdotter, M., Lund, L.H., Winblad, B., Religa, P., Religa, D., 2015.
Heart failure and Alzheimer's disease. J. Intern. Med. 277, 406–425.
Chen, G., Frøkiær, J., Pedersen, M., Nielsen, S., Si, Z., Pang, Q., Stødkilde-Jørgensen, H.,
2008. Reduction of ischemic stroke in rat brain by alpha melanocyte stimulating
hormone. Neuropeptides 42, 331–338.
Chohan, M.O., Li, B., Blanchard, J., Tung, Y.C., Heaney, A.T., Rabe, A., Iqbal, K.,
Grundke-Iqbal, I., 2011. Enhancement of dentate gyrus neurogenesis, dendritic
and synaptic plasticity and memory by a neurotrophic peptide. Neurobiol.
Aging 32, 1420–1434.
Citerio, G., Gaini, S.M., Tomei, G., Stocchetti, N., 2007. Management of 350
aneurysmal subarachnoid hemorrhages in 22 Italian neurosurgical centers.
Intens. Care Med. 33, 1580–1586.
Corander, M.P., Fenech, M., Coll, A.P., 2009. Science of self-preservation: how
melanocortin action in the brain modulates body weight: blood pressure and
ischemic damage. Circulation 120, 2260–2268.
Cunningham, C., 2013. Microglia and neurodegeneration: the role of systemic
inﬂammation. Glia 61, 71–90.
de Wied, D., Bohus, B., 1966. Long term and short term effects on retention of a
conditioned avoidance response in rats by treatment with long acting pitressin
and alpha-MSH. Nature 212, 1484–1486.
de Wied, D.,1969. Effect of peptide hormones on behaviour. In: Ganon, W.F., Martini,
L. (Eds.), Frontiers in Neuroendocrinology. Oxford University Press, London-
New York, pp. 97–140.
Deng, W., Aimone, J.B., Gage, F.H., 2010. New neurons and new memories: how does
adult hippocampal neurogenesis affect learning and memory? Nat. Rev.
Neurosci. 11, 339–350.
Diano, S., 2011. New aspects of melanocortin signaling: a role for PRCP in a-MSH
degradation. Front. Neuroendocrinol. 32, 70–83.
Dmitrieva, V.G., Povarova, O.V., Skvortsova, V.I., Limborska, S.A., Myasoedov, N.F.,
Dergunova, L.V., 2010. Semax and Pro-Gly-Pro activate the transcription of
neurotrophins and their receptor genes after cerebral ischemia. Cell. Mol.
Neurobiol. 30, 71–79.
Dotson, A.L., Offner, H., 2017. Sex differences in the immune response to
experimental stroke: implications for translational research. J. Neurosci. Res. 95,
437–446.
Drouin-Ouellet, J., Cicchetti, F., 2012. Inﬂammation and neurodegeneration: the
story ‘retolled’. Trends Pharmacol. Sci. 33, 542–551.
Duan, X., Kang, E., Liu, C.Y., Ming, G.L., Song, H., 2008. Development of neural stem
cell in the adult brain. Curr. Opin. Neurobiol. 18, 108–115.
Dumont, R.J., Okonkwo, D.O., Verma, S., Hurlbert, R.J., Boulos, P.T., Ellegala, D.B.,
Dumont, A.S., 2001. Acute spinal cord injury, part I: pathophysiologic
mechanisms. Clin. Neuropharmacol. 24, 254–264.
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg,
K., Schellinger, P.D., Bohn, M., Becker, H., Wegrzyn, M., Jähnig, P., Herrmann, M.,
Knauth, M., Bähr, M., Heide, W., Wagner, A., Schwab, S., Reichmann, H.,
Schwendemann, G., Dengler, R., Kastrup, A., Bartels, C., 2009. EPO Stroke Trial
Group: recombinant human erythropoietin in the treatment of acute ischemic
stroke. Stroke 40, 647–656.
Facchinetti, F., Nappi, G., Petraglia, F., Martignoni, E., Sinforiani, E., Genazzani, A.R.,
1984. Central ACTH deﬁcit in degenerative and vascular dementia. Life Sci. 35,
1691–1697.
Ferrari, W., Gessa, G.L., Vargiu, L., 1963. Behavioral effects induced by
intracisternally injected ACTH and MSH. Ann. N.Y. Acad. Sci. 104, 330–345.
Ferrari, W., 1958. Behavioural changes in animals after intracisternal injection with
adrenocorticotrophic hormone and melanocyte-stimulating hormone. Nature
181, 925–926.
Florio, P., Abella, R., Marinoni, E., Di Iorio, R., Li Volti, G., Galvano, F., Galvano, F.,
Pongiglione, G., Frigiola, A., Pinzauti, S., Petraglia, F., Gazzolo, D., 2010.
Biochemical markers of perinatal brain damage. Front. Biosci. 2, 47–72.
Forslin Aronsson, Å., Spulber, S., Popescu, L.M., Winblad, B., Post, C., Oprica, M.,
Schultzberg, M., 2006. a-Melanocyte-stimulating hormone is neuroprotective
in rat global cerebral ischemia. Neuropeptides 40, 65–75.
Forslin Aronsson, Å., Spulber, S., Oprica, M., Winblad, B., Post, C., Schultzberg, M.,
2007. a-MSH rescues neurons from excitotoxic cell death. J. Mol. Neurosci. 33,
239–251.
Friedlander, R.M., 2003. Apoptosis and caspases in neurodegenerative diseases. N.
Engl. J. Med. 348, 1365–1375.
D. Giuliani et al. / Progress in Neurobiology 148 (2017) 40–56 53Frota, E.R., Rodrigues, D.H., Donadi, E.A., Brum, D.G., Maciel, D.R., Teixeira, A.L., 2009.
Increased plasma levels of brain derived neurotrophic factor (BDNF) after
multiple sclerosis relapse. Neurosci. Lett. 460, 130–132.
Gage, F.H., 2000. Mammalian neural stem cells. Science 287, 1433–1438.
Galimberti, D., Baron, P., Meda, L., Prat, E., Scarpini, E., Delgado, R., Catania, A., Lipton,
J.M., Scarlato, G., 1999. a-MSH peptides inhibit production of nitric oxide and
tumor necrosis factor-a by microglial cells activated with beta-amyloid and
interferon gamma. Biochem. Biophys. Res. Commun. 263, 251–256.
Galimberti, D., Ghezzi, L., Scarpini, E., 2013. Immunotherapy against amyloid
pathology in Alzheimer's disease. J. Neurol. Sci. 333, 50–54.
Gao, H.M., Zhou, H., Hong, J.S., 2012. NADPH oxidases: novel therapeutic targets for
neurodegenerative diseases. Trends Pharmacol. Sci. 33, 295–303.
Gatti, S., Lonati, C., Acerbi, F., Sordi, A., Leonardi, P., Carlin, A., Gaini, S.M., Catania, A.,
2012. Protective action of NDP-MSH in experimental subarachnoid hemorrhage.
Exp. Neurol. 234, 230–238.
Getting, S.J., 2006. Targeting melanocortin receptors as potential novel therapeutics.
Pharmacol. Ther. 111, 1–15.
Gispen, W.H., v Wimersma Greidanus, T.B., de Wied, D., 1970. Effects of
hypophysectomy and ACTH 1–10 on responsiveness to electric shock in rats.
Physiol. Behav. 5, 143–146.
Gispen, W.H., Isaacson, R.L., Spruijt, B.M., de Wied, D., 1986. Melanocortins, neural
plasticity and aging: prog. Neuropsychopharmacol. Biol. Psychiatry 10, 415–
426.
Giuliani, D., Leone, S., Mioni, C., Bazzani, C., Zaffe, D., Botticelli, A.R., Altavilla, D.,
Galantucci, M., Minutoli, L., Bitto, A., Squadrito, F., Guarini, S., 2006a. Broad
therapeutic treatment window of the [Nle4, D-Phe7]a-melanocyte-stimulating
hormone for long-lasting protection against ischemic stroke, in Mongolian
gerbils. Eur. J. Pharmacol. 538, 48–56.
Giuliani, D., Mioni, C., Altavilla, D., Leone, S., Bazzani, C., Minutoli, L., Bitto, A.,
Cainazzo, M.M., Marini, H., Zaffe, D., Botticelli, A.R., Pizzala, R., Savio, M., Necchi,
D., Schiöth, H.B., Bertolini, A., Squadrito, F., Guarini, S., 2006b. Both early and
delayed treatment with melanocortin 4 receptor-stimulating melanocortins
produces neuroprotection in cerebral ischemia. Endocrinology 147, 1126–1135.
Giuliani, D., Mioni, C., Bazzani, C., Zaffe, D., Botticelli, A.R., Capolongo, S., Sabba, A.,
Galantucci, M., Iannone, A., Grieco, P., Novellino, E., Colombo, G., Tomasi, A.,
Catania, A., Guarini, S., 2007a. Selective melanocortin MC4 receptor agonists
reverse haemorrhagic shock and prevent multiple organ damage. Br. J.
Pharmacol. 150, 595–603.
Giuliani, D., Ottani, A., Mioni, C., Bazzani, C., Galantucci, M., Minutoli, L., Bitto, A.,
Zaffe, D., Botticelli, A.R., Squadrito, F., Guarini, S., 2007b. Neuroprotection in
focal cerebral ischemia owing to delayed treatment with melanocortins. Eur. J.
Pharmacol. 570, 57–65.
Giuliani, D., Ottani, A., Minutoli, L., Di Stefano, V., Galantucci, M., Bitto, A., Zaffe, D.,
Altavilla, D., Botticelli, A.R., Squadrito, F., Guarini, S., 2009. Functional recovery
after delayed treatment of ischemic stroke with melanocortins is associated
with overexpression of the activity-dependent gene Zif268. Brain Behav.
Immun. 23, 844–850.
Giuliani, D., Ottani, A., Altavilla, D., Bazzani, C., Squadrito, F., Guarini, S., 2010.
Melanocortins and the cholinergic anti-inﬂammatory pathway. Adv. Exp. Med.
Biol. 681, 71–87.
Giuliani, D., Zaffe, D., Ottani, A., Spaccapelo, L., Galantucci, M., Minutoli, L., Bitto, A.,
Irrera, N., Contri, M., Altavilla, D., Botticelli, A.R., Squadrito, F., Guarini, S., 2011.
Treatment of cerebral ischemia with melanocortins acting at MC4 receptors
induces marked neurogenesis and long-lasting functional recovery. Acta
Neuropathol. 122, 443–453.
Giuliani, D., Minutoli, L., Ottani, A., Spaccapelo, L., Bitto, A., Galantucci, M., Altavilla,
D., Squadrito, F., Guarini, S., 2012. Melanocortins as potential therapeutic agents
in severe hypoxic conditions. Front. Neuroendocrinol. 33, 179–193.
Giuliani, D., Ottani, A., Zaffe, D., Galantucci, M., Strinati, F., Lodi, R., Guarini, S., 2013.
Hydrogen sulﬁde slows down progression of experimental Alzheimer's disease
by targeting multiple pathophysiological mechanisms. Neurobiol. Learn. Mem.
104, 82–91.
Giuliani, D., Bitto, A., Galantucci, M., Zaffe, D., Ottani, A., Irrera, N., Neri, L., Cavallini,
G.M., Altavilla, D., Botticelli, A.R., Squadrito, F., Guarini, S., 2014a. Melanocortins
protect against progression of Alzheimer’s disease in triple-transgenic mice by
targeting multiple pathophysiological pathways. Neurobiol. Aging 35, 537–547.
Giuliani, D., Galantucci, M., Neri, L., Canalini, F., Calevro, A., Bitto, A., Ottani, A.,
Vandini, E., Sena, P., Sandrini, M., Squadrito, F., Zaffe, D., Guarini, S., 2014b.
Melanocortins protect against brain damage and counteract cognitive decline in
a transgenic mouse model of moderate Alzheimer’s disease. Eur. J. Pharmacol.
740, 144–150.
Giuliani, D., Neri, L., Canalini, F., Calevro, A., Ottani, A., Vandini, E., Sena, P., Zaffe, D.,
Guarini, S., 2015. NDP-a-MSH induces intense neurogenesis and cognitive
recovery in Alzheimer transgenic mice through activation of melanocortin MC4
receptors. Mol. Cell. Neurosci. 67, 13–21.
Gladstone, D.J., Black, S.E., Hakim, A.M., 2002. Toward wisdom from failure: lessons
from neuroprotective stroke trials and new therapeutic directions. Stroke 33,
2123–2136.
Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., 2010. Mechanisms
underlying inﬂammation in neurodegeneration. Cell 140, 918–934.
Glat, M.J., Offen, D., 2013. Cell and gene therapy in Alzheimer's disease. Stem Cells
Dev. 22, 1490–1496.
Granfeldt, A., Lefer, D.J., Vinten-Johansen, J., 2009. Protective ischaemia in patients:
preconditioning and postconditioning. Cardiovasc. Res. 83, 234–246.
Grieco, P., Carotenuto, A., Auriemma, L., Limatola, A., Di Maro, S., Merlino, F.,
Mangoni, M.L., Luca, V., Di Grazia, A., Gatti, S., Campiglia, P., Gomez-Monterrey,I., Novellino, E., Catania, A., 2013. Novel a-MSH peptide analogues with broad
spectrum antimicrobial activity. PLoS One 8, e61614.
Guarini, S., Rompianesi, E., Ferrari, W., Bertolini, A., 1986. Inﬂuence of vagotomy and
of atropine on the anti-shock effect of adrenocorticotropin. Neuropeptides 8,
19–24.
Guarini, S., Tagliavini, S., Bazzani, C., Ferrari, W., Bertolini, A., 1990. Early treatment
with ACTH-(1–24) in a rat model of hemorrhagic shock prolongs survival and
extends the time-limit for blood reinfusion to be effective. Crit. Care Med. 18,
862–865.
Guarini, S., Bazzani, C., Tagliavini, S., Bertolini, A., Ferrari, W., 1992. Capsaicin
prevents the adrenocorticotropin-induced improvement of cardiovascular
function and survival in hemorrhage-shocked rats. Neurosci. Lett. 143, 181–184.
Guarini, S., Bazzani, C., Mattera Ricigliano, G., Bini, A., Tomasi, A., Bertolini, A., 1996.
Inﬂuence of ACTH-(1–24) on free radical levels in the blood of haemorrhage-
shocked rats: direct ex vivo detection by electron spin resonance spectrometry.
Br. J. Pharmacol. 119, 29–34.
Guarini, S., Bini, A., Bazzani, C., Ricigliano, G.M., Cainazzo, M.M., Tomasi, A., Bertolini,
A., 1997. Adrenocorticotropin normalizes the blood levels of nitric oxide in
haemorrhage-shocked rats. Eur. J. Pharmacol. 336, 15–21.
Guarini, S., Bazzani, C., Cainazzo, M.M., Mioni, C., Ferrazza, G., Vergoni, A.V., Schiöth,
H.B., Wikberg, J.E., Bertolini, A., 1999. Evidence that melanocortin 4 receptor
mediates hemorrhagic shock reversal caused by melanocortin peptides. J.
Pharmacol. Exp. Ther. 291, 1023–1027.
Guarini, S., Altavilla, D., Cainazzo, M.M., Giuliani, D., Bigiani, A., Marini, H., Squadrito,
G., Minutoli, L., Bertolini, A., Marini, R., Adamo, E.B., Venuti, F.S., Squadrito, F.,
2003. Efferent vagal ﬁbre stimulation blunts NF-kB activation and protects
against hypovolemic hemorrhagic shock. Circulation 107, 1189–1194.
Guarini, S., Cainazzo, M.M., Giuliani, D., Mioni, C., Altavilla, D., Marini, H., Bigiani, A.,
Ghiaroni, V., Passaniti, M., Leone, S., Bazzani, C., Caputi, A.P., Squadrito, F.,
Bertolini, A., 2004. Adrenocorticotropin reverses hemorrhagic shock in
anesthetized rats through the rapid activation of a vagal anti-inﬂammatory
pathway. Cardiovasc. Res. 63, 357–365.
Guarini, S., 1996. A highly reproducible model of arterial thrombosis in rats. J.
Pharmacol. Toxicol. Methods 35, 101–105.
Guo, J.L., Lee, V.M., 2014. Cell-to-cell transmission of pathogenic proteins in
neurodegenerative diseases. Nat. Med. 20, 130–138.
Gupta, R., Bathen, M.E., Smith, J.S., Levi, A.D., Bhatia, N.N., Steward, O., 2010.
Advances in the management of spinal cord injury. J. Am. Acad. Orthop. Surg. 18,
210–222.
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R.,
Ekman, M., Faravelli, C., Fratiglioni, L., Gannon, B., Jones, D.H., Jennum, P.,
Jordanova, A., Jönsson, L., Karampampa, K., Knapp, M., Kobelt, G., Kurth, T., Lieb,
R., Linde, M., Ljungcrantz, C., Maercker, A., Melin, B., Moscarelli, M., Musayev, A.,
Norwood, F., Preisig, M., Pugliatti, M., Rehm, J., Salvador-Carulla, L., Schlehofer,
B., Simon, R., Steinhausen, H.C., Stovner, L.J., Vallat, J.M., den Bergh, P.V., van Os,
J., Vos, P., Xu, W., Wittchen, H.U., Jönsson, B., Olesen, J., 2011. Cost of disorders of
the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 718–779.
Haass, C., 2010. Initiation and propagation of neurodegeneration. Nat. Med. 16,
1201–1204.
Halabe Bucay, A., 2008. Activation of the proopiomelanocortin gene with
ketoconazole as a treatment for Parkinson's disease: a new hypothesis. Ann. N.
Y. Acad. Sci. 1144, 237–242.
Hayes, M., Zavazava, N., 2013. Strategies to generate induced pluripotent stem cells.
Methods Mol. Biol. 1029, 77–92.
Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L.,
Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., Herrup, K., Frautschy, S.
A., Finsen, B., Brown, G.C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E.,
Halle, A., Petzold, G.C., Town, T., Morgan, D., Shinohara, M.L., Perry, V.H., Holmes,
C., Bazan, N.G., Brooks, D.J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O.,
Boddeke, E., Dinarello, C.A., Breitner, J.C., Cole, G.M., Golenbock, D.T., Kummer,
M.P., 2015. Neuroinﬂammation in Alzheimer’s disease. Lancet Neurol. 14, 388–
405.
Ho, W.L., Leung, Y., Tsang, A.W., So, K.F., Chiu, K., Chang, R.C., 2012. Tauopathy in the
retina and optic nerve: does it shadow pathological changes in the brain? Mol.
Vis. 18, 2700–2710.
Holloway, P.M., Smith, H.K., Renshaw, D., Flower, R.J., Getting, S.J., Gavins, F.N.E.,
2011. Targeting the melanocortin receptor system for anti-stroke therapy.
Trends Pharmacol. Sci. 32, 90–98.
Huang, Q., Tatro, J.B., 2002. a-Melanocyte stimulating hormone suppresses
intracerebral tumor necrosis factor-a and interleukin-1b gene expression
following transient cerebral ischemia in mice. Neurosci. Lett. 334, 186–190.
Huh, S.K., Lipton, J.M., Batjer, H.H., 1997. The protective effects of a-melanocyte
stimulating hormone on canine brain ischemia. Neurosurgery 40, 132–140.
Imayoshi, I., Sakamoto, M., Ohtsuka, T., Takao, K., Miyakawa, T., Yamaguchi, M., Mori,
K., Ikeda, T., Itohara, S., Kageyama, R., 2008. Roles of continuous neurogenesis in
the structural and functional integrity of the adult forebrain. Nat. Neurosci. 11,
1153–1161.
Inestrosa, N.C., Arenas, E., 2010. Emerging roles of Wnts in the adult nervous system.
Nat. Rev. Neurosci. 11, 77–86.
Iqbal, K., Grundke-Iqbal, I., 2010. Alzheimer's disease, a multifactorial disorder
seeking multitherapies. Alzheimers Dement 6, 420–424.
Iqbal, K., Grundke-Iqbal, I., 2011. Opportunities and challenges in developing
Alzheimer disease therapeutics. Acta Neuropathol. 122, 543–549.
Irwin, R.W., Brinton, R.D., 2014. Allopregnanolone as regenerative therapeutic for
Alzheimer's disease: translational development and clinical promise. Prog.
Neurobiol. 113, 40–55.
54 D. Giuliani et al. / Progress in Neurobiology 148 (2017) 40–56Ittner, L.M., Götz, J., 2011. Amyloid-b and tau — a toxic pas de deux in Alzheimer's
disease. Nat. Rev. Neurosci. 12, 65–72.
Iturri Clavero, F., González Uriarte, A., Tamayo Medel, G., Pomposo Gaztelu, I.C., Cano
Dorronsoro, M., Martínez Ruiz, A., 2010. Perioperative considerations in vagal
nerve stimulator implantation. Rev. Esp. Anestesiol. Reanim. 57, 431–438.
Jakovcevski, M., Akbarian, S., 2012. Epigenetic mechanisms in neurological disease.
Nat. Med. 18, 1194–1204.
Jessberger, S., Kempermann, G., 2003. Adult-born hippocampal neurons mature into
activity-dependent responsiveness. Eur. J. Neurosci. 18, 2707–2712.
Jochem, J., 2004. Involvement of proopiomelanocortin-derived peptides in
endogenous central istamine-induced reversal of critical haemorrhagic
hypotension in rats. J. Physiol. Pharmacol. 55, 57–71.
Kabadi, S.V., Faden, A.I., 2014. Neuroprotective strategies for traumatic brain injury:
improving clinical translation. Int. J. Mol. Sci. 15, 1216–1236.
Karbowski, M., Neutzner, A., 2012. Neurodegeneration as a consequence of failed
mitochondrial maintenance. Acta Neuropathol. 123, 157–171.
Kazanis, I., 2009. The subependymal zone neurogenic niche: a beating heart in the
centre of the brain. Brain 132, 2909–2921.
Kourbeti, I.S., Vakis, A.F., Papadakis, J.A., Karabetsos, D., Bertsias, G., Filippou, M.,
Ioannou, A., Neophytou, C., Anastasaki, M., Samonis, G., 2012. Infections in
traumatic brain injury patients. Clin. Microbiol. Infect. 18, 359–364.
Krizbai, I.A., Lenzser, G., Szatmari, E., Farkas, A.E., Wilhelm, I., Fekete, Z., Erdos, B.,
Bauer, H., Bauer, H.C., Sandor, P., Komjati, K., 2005. Blood-brain barrier changes
during compensated and decompensated hemorrhagic shock. Shock 24, 428–
433.
Kumar, A., Loane, D.J., 2012. Neuroinﬂammation after traumatic brain injury:
opportunities for therapeutic intervention. Brain Behav. Immun. 26, 1191–1201.
Kuwabara, T., Hsieh, J., Muotri, A., Yeo, G., Warashina, M., Lie, D.C., Moore, L.,
Nakashima, K., Asashima, M., Gage, F.H., 2009. Wnt-mediated activation of
NeuroD1 and retro-elements during adult neurogenesis. Nat. Neurosci. 12,
1097–1105.
Lanterna, L.A., Rigoldi, M., Tredici, G., Biroli, F., Cesana, C., Gaini, S.M., Dalprà, L.,
2005. APOE inﬂuences vasospasm and cognition of noncomatose patients with
subarachnoid hemorrhage. Neurology 64, 1238–1244.
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H.W.M., Mastroeni, D.,
Coleman, P., Lemere, C.A., Hof, P.R., van den Hove, D.L.A., Rutten, B.P.F., 2015. The
epigenetics of aging and neurodegeneration. Prog. Neurobiol. 131, 21–64.
Lasaga, M., Debeljuk, L., Durand, D., Scimonelli, T.N., Caruso, C., 2008. Role of
a-melanocyte stimulating hormone and melanocortin 4 receptor in brain
inﬂammation. Peptides 29, 1825–1835.
Laskowitz, D.T., Kolls, B.J., 2010. Neuroprotection in subarachnoid hemorrhage.
Stroke 41, S79–S84.
Lazarov, O., Mattson, M.P., Peterson, D.A., Pimplikar, S.W., van Praag, H., 2010. When
neurogenesis encounters aging and disease. Trends Neurosci. 33, 569–579.
Lee, J.H., Gleeson, J.G., 2010. The role of primary cilia in neuronal function.
Neurobiol. Dis. 38, 167–172.
Lee, S.T., Chu, K., Jung, K.H., Kang, K.M., Kim, J.H., Bahn, J.J., Jeon, D., Kim, M., Lee, S.K.,
Roh, J.K., 2010. Cholinergic anti-inﬂammatory pathway in intracerebral
hemorrhage. Brain Res. 1309, 164–171.
Leker, R.R., Shohami, E., 2002. Cerebral ischemia and trauma-different etiologies yet
similar mechanisms: neuroprotective opportunities. Brain Res. Rev. 39, 55–73.
Leuner, K., Müller, W.E., Reichert, A.S., 2012. From mitochondrial dysfunction to
amyloid beta formation: novel insights into the pathogenesis of Alzheimer's
disease. Mol. Neurobiol. 46, 186–193.
Lichtenwalner, R.J., Parent, J.M., 2006. Adult neurogenesis and the ischemic
forebrain. J. Cereb. Blood Flow Metab. 26, 1–20.
Lie, D.C., Song, H., Colamarino, S.A., Ming, G.L., Gage, F.H., 2004. Neurogenesis in the
adult brain: new strategies for central nervous system diseases. Annu. Rev.
Pharmacol. Toxicol. 44, 399–421.
Lilja, A.M., Röjdner, J., Mustaﬁz, T., Thomé, C.M., Storelli, E., Gonzalez, D., Unger-
Lithner, C., Greig, N.H., Nordberg, A., Marutle, A., 2013. Age-dependent
neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of
brain amyloid-b levels. PLoS One 8, e58752.
Lindvall, O., Kokaia, Z., 2010. Stem cells in human neurodegenerative disorders —
time for clinical translation? J. Clin. Invest. 120, 29–40.
Liu, J., Solway, K., Messing, R.O., Sharp, F.R., 1998. Increased neurogenesis in the
dentate gyrus after transient global ischemia in gerbils. J. Neurosci. 18, 7768–
7778.
Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T.B., Flegal, K.,
Ford, E., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S., Ho, M., Howard, V.,
Kissela, B., Kittner, S., Lackland, D., Lisabeth, L., Marelli, A., McDermott, M.,
Meigs, J., Mozaffarian, D., Nichol, G., O'Donnell, C., Roger, V., Rosamond, W.,
Sacco, R., Sorlie, P., Stafford, R., Steinberger, J., Thom, T., Wasserthiel-Smoller, S.,
Wong, N., Wylie-Rosett, J., Hong, Y., American Heart Association Statistics
Committee and Stroke Statistics Subcommittee, 2009. Heart disease and stroke
statistics-2009 update: a report from the American Heart Association Statistics
Committee and Stroke Statistics Subcommittee. Circulation 119, e182.
Lo, E.H., 2010. Degeneration and repair in central nervous system disease. Nat. Med.
16, 1205–1209.
Loane, D.J., Faden, A.I., 2010. Neuroprotection for traumatic brain injury:
translational challenges and emerging therapeutic strategies. Trends
Pharmacol. Sci. 31, 596–604.
Lonati, C., Sordi, A., Giuliani, D., Spaccapelo, L., Leonardi, P., Carlin, A., Ottani, A.,
Galantucci, M., Grieco, P., Catania, A., Guarini, S., 2012. Molecular changes
induced in rat liver by hemorrhage and effects of melanocortin treatment.
Anesthesiology 116, 692–700.Losiniecki, A., Shutter, L., 2010. Management of traumatic brain injury. Curr. Treat.
Options Neurol. 12, 142–154.
Louvi, A., Grove, E.A., 2011. Cilia in the CNS: the quiet organelle claims center stage.
Neuron 69, 1046–1060.
Ma, K., McLaurin, J., 2014. a-Melanocyte stimulating hormone prevents GABAergic
neuronal loss and improves cognitive function in Alzheimer's disease. J.
Neurosci. 34, 6736–6745.
Macdonald, R.L., Pluta, R.M., Zhang, J.H., 2007. Cerebral vasospasm after
subarachnoid hemorrhage: the emerging revolution. Nat. Clin. Pract. Neurol. 3,
256–263.
Maddahi, A., Ansar, S., Chen, Q., Edvinsson, L., 2011. Blockade of the MEK/ERK
pathway with a raf inhibitor prevents activation of pro-inﬂammatory mediators
in cerebral arteries and reduction in cerebral blood ﬂow after subarachnoid
hemorrhage in a rat model. J. Cereb. Blood Flow Metab. 31, 144–154.
Maegele, M., Engel, D., Bouillon, B., Lefering, R., Fach, H., Raum, M., Buchheister, B.,
Schaefer, U., Klug, N., Neugebauer, E., 2007. Incidence and outcome of traumatic
brain injury in an urban area in Western Europe over 10 years. Eur. Surg. Res. 39,
372–379.
Magnoni, S., Stocchetti, N., Colombo, G., Carlin, A., Colombo, A., Lipton, J.M., Catania,
A., 2003. a-Melanocyte stimulating hormone is decreased in plasma of patients
with acute brain injury. J. Neurotrauma 20, 251–260.
Marion, D., Bullock, M.R., 2009. Current and future role of therapeutic hypothermia.
J. Neurotrauma 26, 455–467.
Marlatt, M.W., Lucassen, P.J., 2010. Neurogenesis and Alzheimer's disease: biology
and pathophysiology in mice and men. Curr. Alzheimer Res. 7, 113–125.
Masuda, T., Isobe, Y., Aihara, N., Furuyama, F., Misumi, S., Kim, T.S., Nishino, H., Hida,
H., 2007. Increase in neurogenesis and neuroblast migration after a small
intracerebral hemorrhage in rats. Neurosci. Lett. 425, 114–119.
Maybhate, A., Hu, C., Bazley, F.A., Yu, Q., Thakor, N.V., Kerr, C.L., All, A.H., 2012.
Potential long-term beneﬁts of acute hypothermia after spinal cord injury:
assessments with somatosensory-evoked potentials. Crit. Care Med. 40, 573–
579.
Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R., Sharma, P.L., 2013. Excitotoxicity:
bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol.
698, 6–18.
Michalski, D., Grosche, J., Pelz, J., Schneider, D., Weise, C., Bauer, U., Kacza, J., Gärtner,
U., Hobohm, C., Härtig, W., 2010. A novel quantiﬁcation of blood-brain barrier
damage and histochemical typing after embolic stroke in rats. Brain Res. 1359,
186–200.
Minutoli, L., Bitto, A., Squadrito, F., Irrera, N., Rinaldi, M., Nicotina, P.A., Arena, S.,
Magno, C., Marini, H., Spaccapelo, L., Ottani, A., Giuliani, D., Romeo, C., Guarini,
S., Antonuccio, P., Altavilla, D., 2011a. Melanocortin 4 receptor activation
protects against testicular ischemia-reperfusion injury by triggering the
cholinergic antinﬂammatory pathway. Endocrinology 152, 3852–3861.
Minutoli, L., Squadrito, F., Nicotina, P.A., Giuliani, D., Ottani, A., Polito, F., Bitto, A.,
Irrera, N., Guzzo, G., Spaccapelo, L., Fazzari, C., Macrì, A., Marini, H., Guarini, S.,
Altavilla, D., 2011b. Melanocortin 4 receptor stimulation decreases pancreatitis
severity in rats by activation of the cholinergic anti-inﬂammatory pathway. Crit.
Care Med. 39, 1089–1096.
Mioni, C., Giuliani, D., Cainazzo, M.M., Leone, S., Iannone, C., Bazzani, C., Grieco, P.,
Novellino, E., Tomasi, A., Bertolini, A., Guarini, S., 2003. Further evidence that
melanocortins prevents myocardial reperfusion injury by activating
melanocortin MC3 receptors. Eur. J. Pharmacol. 477, 227–234.
Mioni, C., Bazzani, C., Giuliani, D., Altavilla, D., Leone, S., Ferrari, A., Minutoli, L., Bitto,
A., Marini, H., Zaffe, D., Botticelli, A.R., Iannone, A., Tomasi, A., Bigiani, A.,
Bertolini, A., Squadrito, F., Guarini, S., 2005. Activation of an efferent cholinergic
pathway produces strong protection against myocardial ischemia/reperfusion
injury in rats. Crit. Care Med. 33, 2621–2628.
Moore, E.M., Nichol, A.D., Bernard, S.A., Bellomo, R., 2011. Therapeutic hypothermia:
beneﬁts, mechanisms and potential clinical applications in neurological, cardiac
and kidney injury. Injury 42, 843–854.
Moretti, A., Ferrari, F., Villa, R.F., 2015. Neuroprotection for ischaemic stroke: current
status and challenges. Pharmacol. Ther. 146, 23–34.
Morita, Y., Takizawa, S., Kamiguchi, H., Uesugi, T., Kawada, H., Takagi, S., 2007.
Administration of hematopoietic cytokines increases the expression of anti-
inﬂammatory cytokine (IL-10) mRNA in the subacute phase after stroke.
Neurosci. Res. 58, 356–360.
Moskowitz, M.A., Lo, E.H., Iadecola, C., 2010. The science of stroke: mechanisms in
search of treatments. Neuron 67, 181–198.
Mountjoy, K.G., Robbins, L.S., Mortrud, M.T., Cone, R.D., 1992. The cloning of a family
of genes that encode the melanocortin receptors. Science 257, 1248–1251.
Mountjoy, K.G., Guan, J., Elia, C.J., Sirimanne, E.S., Williams, C.E.,1999. Melanocortin-
4 receptor messenger RNA expression is up-regulated in the non-damaged
striatum following unilateral hypoxic-ischaemic brain injury. Neuroscience 89,
183–190.
Mountjoy, K.G., 2010. Distribution and function of melanocortin receptors within
the brain. Adv. Exp. Med. Biol. 681, 29–48.
Mravec, B., 2010. The role of the vagus nerve in stroke. Auton. Neurosci. 158, 8–12.
Mu, Y., Gage, F.H., 2011. Adult hippocampal neurogenesis and its role in Alzheimer's
disease. Mol. Neurodegener. 6, 85.
Myers, D.A., Bell, P.A., Hyatt, K., Mlynarczyk, M., Ducsay, C.A., 2005. Long-term
hypoxia enhances proopiomelanocortin processing in the near-term ovine
fetus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, 1178–1184.
Nagahara, A.H., Tuszynski, M.H., 2011. Potential therapeutic uses of BDNF in
neurological and psychiatric disorders. Nat. Rev. Drug Discov. 10, 209–219.
D. Giuliani et al. / Progress in Neurobiology 148 (2017) 40–56 55Naggara, O., Nataf, F., 2013. Subarachnoid hemorrhage in young patients. Rev. Prat.
63, 951–959.
Narla, S., Klejbor, I., Birkaya, B., Lee, Y.W., Morys, J., Stachowiak, E.K., Terranova, C.,
Bencherif, M., Stachowiak, M.K., 2013. a7 Nicotinic receptor agonist reactivates
neurogenesis in adult brain. Biochem. Pharmacol. 86, 1099–1104.
O’Bryant, S.E., Mielke, M.M., Rissman, R.A., Lista, S., Vanderstichele, H., Zetterberg,
H., Lewczuk, P., Posner, H., Hall, J., Johnson, L., Fong, Y.L., Luthman, J., Jeromin, A.,
Batrla-Utermann, R., Villarreal, A., Britton, G., Snyder, P.J., Henriksen, K.,
Grammas, P., Gupta, V., Martins, R., Hampel, H., Bioﬂuid Based Biomarker
Professional Interest Area, 2016. Blood-based biomarkers in Alzheimer disease:
Current state of the science and a novel collaborative paradigm for advancing
from discovery to clinic. Alzheimers Dement. 552–5260 (16), 4–33056.
O’Collins, V.E., Macleod, M.R., Donnan, G.A., Horky, L.L., van der Worp, B.H., Howells,
D.W., 2006. 1, 026 experimental treatments in acute stroke. Ann. Neurol. 59,
467–477.
O’Donohue, T.I., Dorsa, D.M., 1982. The opiomelanotropinergic neuronal and
endocrine systems. Peptides 3, 353–395.
Ohira, K., 2011. Injury-induced neurogenesis in the mammalian forebrain. Cell. Mol.
Life Sci. 68, 1645–1656.
Oosterom, J., Nijenhuis, W.A., Schaaper, W.M., Slootstra, J., Meloen, R.H., Gispen, W.
H., Burbach, J.P., Adan, R.A., 1999. Conformation of the core sequence in
melanocortin peptides directs selectivity for the melanocortin MC3 and MC4
receptors. J. Biol. Chem. 274, 16853–16860.
Ottani, A., Giuliani, D., Mioni, C., Galantucci, M., Minutoli, L., Bitto, A., Altavilla, D.,
Zaffe, D., Botticelli, A.R., Squadrito, F., Guarini, S., 2009. Vagus nerve mediates
the protective effects of melanocortins against cerebral and systemic damage
after ischemic stroke. J. Cereb. Blood Flow Metab. 29, 512–523.
Ottani, A., Galantucci, M., Ardimento, E., Neri, L., Canalini, F., Calevro, A., Zaffe, D.,
Novellino, E., Grieco, P., Giuliani, D., Guarini, S., 2013. Modulation of the JAK/
ERK/STAT signaling in melanocortin-induced inhibition of local and systemic
responses to myocardial ischemia/reperfusion. Pharmacol. Res. 72, 1–8.
Ottani, A., Neri, L., Canalini, F., Calevro, A., Rossi, R., Cappelli, G., Ballestri, M., Giuliani,
D., Guarini, S., 2014. Protective effects of the melanocortin analog NDP-a-MSH
in rats undergoing cardiac arrest. Eur. J. Pharmacol. 745, 108–116.
Patel, H.B., Leoni, G., Melendez, T.M., Sampaio, A.L., Perretti, M., 2010. Melanocortin
control of cell trafﬁcking in vascular inﬂammation. Adv. Exp. Med. Biol. 681, 88–
106.
Raff, H., Goldmann, R.W., Kindwall, E.P., 1985. Adrenocortical function after acute
carbon monoxide exposure in humans. Arch Environ. Health 40, 88–90.
Rainero, I., May, C., Kaye, J.A., Friedland, R.P., Rapoport, S.I., 1988. CSF a-MSH in
dementia of the Alzheimer type. Neurology 38, 1281–1284.
Raj, A., Kuceyeski, A., Weiner, M., 2012. A network diffusion model of disease
progression in dementia. Neuron 73, 1204–1215.
Ramee, S.R., White, C.J., 2014. Acute stroke intervention. Curr. Probl. Cardiol. 39, 59–
76.
Regan, C., Shepherd, C., Strack, A., Weinberg, D., Nargund, R., Ye, Z., Polard, P., Fong, T.,
Renolds, I., Lynch, J., 2009. Lack of protection with a novel, selective
melanocortin receptor subtype-4 agonist RY767 in a rat transient middle
cerebral artery occlusion stroke model. Pharmacology 83, 38–44.
Revesz, D., Tjernstrom, M., Ben-Menachem, E., Thorlin, T., 2008. Effects of vagus
nerve stimulation on rat hippocampal progenitor proliferation. Exp. Neurol.
214, 259–265.
Rodrigues, M.C.O., Voltarelli, J., Sanberg, P.R., Allickson, J.G., Kuzmin-Nichols, N.,
Garbuzova-Davis, S., Borlongan, C.V., 2012. Recent progress in cell therapy for
basal ganglia disorders with emphasis on menstrual blood transplantation in
stroke. Neurosci. Biobehav. Rev. 36, 177–190.
Rogalewski, A., Schneider, A., Ringelstein, E.B., Schäbitz, W.R., 2006. Toward a
multimodal neuroprotective treatment of stroke. Stroke 37, 1129–1136.
Rosas-Ballina, M., Olofsson, P.S., Ochani, M., Valdés-Ferrer, S.I., Levine, Y.A., Reardon,
C., Tusche, M.W., Pavlov, V.A., Andersson, U., Chavan, S., Mak, T.W., Tracey, K.J.,
2011. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve
circuit. Science 334, 98–101.
Salerian, A.J., Saleri, N.G., 2008. Cooling core body temperature may slow down
neurodegeneration. CNS Spectr. 13, 227–229.
Sandyk, R., Awerbuch, G.I., 1992. Nocturnal plasma melatonin and alpha-
melanocyte stimulating hormone levels during exacerbation of multiple
sclerosis. Int. J. Neurosci. 67, 173–186.
Savos, A.V., Gee, J.M., Zierath, D., Becker, K.J., 2011. a-MSH: a potential
neuroprotective and immunomodulatory agent for the treatment of stroke. J.
Cereb. Blood Flow Metab. 31, 606–613.
Schiöth, H.B., Haitina, T., Ling, M.K., Ringholm, A., Fredriksson, R., Cerdá-Reverter, J.
M., Klovins, J., 2005. Evolutionary conservation of the structural,
pharmacological, and genomic characteristics of the melanocortin receptor
subtypes. Peptides 26, 1886–1900.
Schiöth, H.B., Craft, S., Brooks, S.J., Frey 2nd, W.H., Benedict, C., 2012. Brain insulin
signaling and Alzheimer's disease: current evidence and future directions. Mol.
Neurobiol. 46, 4–10.
Schiöth, H.B., 2001. The physiological role of melanocortin receptors. Vitam. Horm.
63, 195–232.
Schneider, C.P., Schwacha, M.G., Chaudry, I.H., 2004. The role of interleukin-10 in the
regulation of the systemic inﬂammatory response following trauma-
hemorrhage. Biochim. Biophys. Acta. 1689, 22–32.
Schumacher, M., Mattern, C., Ghoumari, A., Oudinet, J.P., Liere, P., Labombarda, F.,
Sitruk-Ware, R., De Nicola, A.F., Guennoun, R., 2014. Revisiting the roles of
progesterone and allopregnanolone in the nervous system: resurgence of the
progesterone receptors. Prog. Neurobiol. 113, 6–39.Sharma, H.S., Skottner, A., Lundstedt, T., Flärdh, M., Wiklund, L., 2006.
Neuroprotective effects of melanocortins in experimental spinal cord injury An
experimental study in the rat using topical application of compounds with
varying afﬁnity to melanocortin receptors. J. Neural. Transm. 113, 463–476.
Sharma, H.S., Castellani, R.J., Smith, M.A., Sharma, A., 2012. The blood-brain barrier
in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. Int.
Rev. Neurobiol. 102, 47–90.
Shen, J., Xie, L., Mao, X., Zhou, Y., Zhan, R., Greenberg, D.A., Jin, K., 2008. Neurogenesis
after primary intracerebral hemorrhage in adult human brain. J. Cereb. Blood
Flow Metab. 28, 1460–1468.
Shen, Y., Fu, W.Y., Cheng, E.Y., Fu, A.K., Ip, N.Y., 2013. Melanocortin-4 receptor
regulates hippocampal synaptic plasticity through a protein kinase A-
dependent mechanism. J. Neurosci. 33, 464–472.
Siljee-Wong, J.E., Valle, M.I., Zhang, S., Ersoy, B.A., Reiter, J., Vaisse, C., 2010. The
melanocortin 4 receptor localizes and may function at the primary cilium.
Abstract 6th International Melanocortin Meeting, Utrecht, 8–11 July 2010, pp.
57.
Silva, N.A., Sousa, N., Reis, R.L., Salgado, A.J., 2014. From basics to clinical: a
comprehensive review on spinal cord injury. Prog. Neurobiol. 114, 25–57.
Simamura, E., Shimada, H., Shoji, H., Otani, H., Hatta, T., 2011. Effects of
melanocortins on fetal development. Congenit. Anom. 51, 47–54.
Sivak, J.M., 2013. The aging eye: common degenerative mechanisms between the
Alzheimer’s brain and retinal disease. Invest. Ophthalmol. Vis. Sci. 54, 871–880.
Sivanandam, T.M., Thakur, M.K., 2012. Traumatic brain injury: a risk factor for
Alzheimer’s disease. Neurosci. Biobehav. Rev. 36, 1376–1381.
Sofroniew, M.V., 2015. Astrocyte barriers to neurotoxic inﬂammation. Nat. Rev.
Neurosci. 16, 249–263.
Spaccapelo, L., Bitto, A., Galantucci, M., Ottani, A., Irrera, N., Minutoli, L., Altavilla, D.,
Novellino, E., Grieco, P., Zaffe, D., Squadrito, F., Giuliani, D., Guarini, S., 2011.
Melanocortin MC4 receptor agonists counteract late inﬂammatory and
apoptotic responses and improve neuronal functionality after cerebral
ischemia. Eur. J. Pharmacol. 670, 479–486.
Spaccapelo, L., Galantucci, M., Neri, L., Contri, M., Pizzala, R., D’Amico, R., Ottani, A.,
Zaffe, D., Giuliani, D., Guarini, S., 2013. Up-regulation of the canonical Wnt-3A
and Sonic hedgehog signalling underlies melanocortin-induced neurogenesis
after cerebral ischemia. Eur. J. Pharmacol. 707, 78–86.
Spalding, K.L., Bergmann, O., Alkass, K., Bernard, S., Salehpour, M., Huttner, H.B.,
Boström, E., Westerlund, I., Vial, C., Buchholz, B.A., Possnert, G., Mash, D.C.,
Druid, H., Frisén, J., 2013. Dynamics of hippocampal neurogenesis in adult
humans. Cell 153, 1219–1227.
Spence, R.D., Voskuhl, R.R., 2012. Neuroprotective effects of estrogens and
androgens in CNS inﬂammation and neurodegeneration. Front.
Neuroendocrinol. 33, 105–115.
Sperling, R.A., Karlawish, J., Johnson, K.A., 2013. Preclinical Alzheimer disease — the
challenges ahead. Nat. Rev. Neurol. 9, 54–58.
Spulber, S., Moldovan, M., Oprica, M., Aronsson, A.F., Post, C., Winblad, B.,
Schultzberg, M., 2005. a-MSH decreases core and brain temperature during
global cerebral ischemia in rats. Neuroreport 16, 69–72.
Starowicz, K., Przewłocka, B., 2003. The role of melanocortins and their receptors in
inﬂammatory processes: nerve regeneration and nociception. Life Sci. 73, 823–
847.
Stavchansky, V.V., Yuzhakov, V.V., Botsina, A.Y., Skvortsova, V.I., Bondurko, L.N.,
Tsyganova, M.G., Limborska, S.A., Myasoedov, N.F., Dergunova, L.V., 2011. The
effect of semax and its C-end peptide PGP on the morphology and proliferative
activity of rat brain cells during experimental ischemia: a pilot study. J. Mol.
Neurosci. 45, 177–185.
Stetler, R.A., Leak, R.K., Gan, Y., Li, P., Zhang, F., Hu, X., Jing, Z., Chen, J., Zigmond, M.J.,
Gao, Y., 2014. Preconditioning provides neuroprotection in models of CNS
disease: paradigms and clinical signiﬁcance. Prog. Neurobiol. 114, 58–83.
Suh, H., Deng, W., Gage, F.H., 2009. Signaling in adult neurogenesis. Annu. Rev. Cell
Dev. Biol. 25, 253–275.
Sun, Y., Jin, K., Xie, L., Childs, J., Mao, X.O., Logvinova, A., Greenberg, D.A., 2003. VEGF-
induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral
ischemia. J. Clin. Invest. 111, 1843–1851.
Suzuki, S., Gerhold, L.M., Böttner, M., Rau, S.W., Dela Cruz, C., Yang, E., Zhu, H., Yu, J.,
Cashion, A.B., Kindy, M.S., Merchenthaler, I., Gage, F.H., Wise, P.M., 2007.
Estradiol enhances neurogenesis following ischemic stroke through estrogen
receptors alpha and beta. J. Comp. Neurol. 500, 1064–1075.
Sy, M., Kitazawa, M., Medeiros, R., Whitman, L., Cheng, D., Lane, T.E., Laferla, F.M.,
2011. Inﬂammation induced by infection potentiates tau pathological features
in transgenic mice. Am. J. Pathol. 178, 2811–2822.
Tashiro, A., Makino, H., Gage, F.H., 2007. Experience-speciﬁc functional modiﬁcation
of the dentate gyrus through adult neurogenesis: a critical period during an
immature stage. J. Neurosci. 27, 3252–3259.
Tatro, J.B., Entwistle, M.L., 1994. Distribution of melanocortin receptors in the lower
brainstem of the rat. Ann. N.Y. Acad. Sci. 739, 311–314.
Tatro, J.B., Sinha, P.S., 2003. The central melanocortin system and fever. Ann. N. Y.
Acad. Sci. 994, 246–257.
Tatro, J.B., 1990. Melanotropin receptors in the brain are differentially distributed
and recognize both corticotrophin and alpha-melanocyte stimulating hormone.
Brain Res. 536, 124–132.
Tatro, J.B., 1996. Receptor biology of the melanocortins, a family of
neuroimmunomodulatory peptides. Neuroimmunomodulation 3, 259–284.
Tatro, J.B., 2006. Melanocortins defend their territory: multifaceted neuroprotection
in cerebral ischemia. Endocrinology 147, 1122–1125.
56 D. Giuliani et al. / Progress in Neurobiology 148 (2017) 40–56Tayeb, H.O., Yang, H.D., Price, B.H., Tarazi, F.I., 2012. Pharmacotherapies for
Alzheimer’s disease: beyond cholinesterase inhibitors. Pharmacol. Ther. 134, 8–
25.
Tracey, K.J., 2002. The inﬂammatory reﬂex. Nature 420, 853–859.
Tracey, K.J., 2007. Physiology and immunology of the cholinergic antiinﬂammatory
pathway. J. Clin. Invest. 117, 289–296.
Van der Walt, A., Butzkueven, H., Kolbe, S., Marriott, M., Alexandrou, E., Gresle, M.,
Egan, G., Kilpatrick, T., 2010. Neuroprotection in multiple sclerosis: a
therapeutic challenge for the next decade. Pharmacol. Ther. 126, 82–93.
Vaquero, J., Zurita, M., 2011. Functional recovery after severe CNS trauma: current
perspectives for cell therapy with bone marrow stromal cells. Prog. Neurobiol.
93, 341–349.
Veighey, K., Macallister, R.J., 2012. Clinical applications of remote ischemic
preconditioning. Cardiol. Res. Pract. 2012, 620681.
Vergoni, A.V., Bertolini, A., 2000. Role of melanocortins in the central control of
feeding. Eur. J. Pharmacol. 405, 25–32.
Versteeg, D.H.G., Van Bergen, P., Adan, R.A.H., De Wildt, D.J., 1998. Melanocortins
and cardiovascular regulation. Eur. J. Pharmacol. 360, 1–14.
Vessal, M., Aycock, A., Garton, M.T., Ciferri, M., Darian-Smith, C., 2007. Adult
neurogenesis in primate and rodent spinal cord: comparing a cervical dorsal
rhizotomy with a dorsal column transection. Eur. J. Neurosci. 26, 2777–2794.
Veyrac, A., Gros, A., Bruel-Jungerman, E., Rochefort, C., Kleine Borgmann, F.B.,
Jessberger, S., Laroche, S., 2013. Zif268/egr1 gene controls the selection,
maturation and functional integration of adult hippocampal newborn neurons
by learning. Proc. Natl. Acad. Sci. U. S. A. 110, 7062–7067.
Vikman, P., Beg, S., Khurana, T.S., Hansen-Schwartz, J., Edvinsson, L., 2006. Gene
expression and molecular changes in cerebral arteries following subarachnoid
hemorrhage in the rat. J. Neurosurg. Sci. 105, 438–444.
Vila, N., Castillo, J., Dávalos, A., Esteve, A., Planas, A.M., Chamorro, A., 2003. Levels of
anti-inﬂammatory cytokines and neurological worsening in acute ischemic
stroke. Stroke 34, 671–675.
Vonck, K., Raedt, R., Naulaerts, J., De Vogelaere, F., Thiery, E., Van Roost, D.,
Aldenkamp, B., Miatton, M., Boon, P., 2014. Vagus nerve stimulation . . . 25 years
later! What do we know about the effects on cognition? Neurosci. Biobehav.
Rev. 45, 63–71.
Walsh, J.G., Muruve, D.A., Power, C., 2014. Inﬂammasomes in the CNS. Nat. Rev.
Neurosci. 15, 84–97.
Wang, L., Zhang, Z., Wang, Y., Zhang, R., Chopp, M., 2004. Treatment of stroke with
erythropoietin enhances neurogenesis and angiogenesis and improves
neurological function in rats. Stroke 35, 1732–1737.
Westendorp, W.F., Nederkoorn, P.J., Vermeij, J.D., Dijkgraaf, M.G., van de Beek, D.,
2011. Post-stroke infection: a systematic review and meta-analysis. BMC
Neurol. 11, 110.
Wikberg, J.E., Mutulis, F., 2008. Targeting melanocortin receptors: an approach to
treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov. 7, 307–
323.Wikberg, J.E.S., Muceniece, R., Mandrika, I., Prusis, P., Lindblom, J., Post, C., Skottner,
A., 2000. New aspects on the melanocortins and their receptors. Pharmacol. Res.
42, 393–420.
Wiltrout, C., Lang, B., Yan, Y., Dempsey, R.J., Vemuganti, R., 2007. Repairing brain
after stroke: a review on post-ischemic neurogenesis. Neurochem. Int. 50,1028–
1041.
Xi, G., Keep, R.F., Hoff, J.T., 2006. Mechanisms of brain injury after intracerebral
haemorrhage. Lancet Neurol. 5, 53–63.
Xin, J., Wainwright, D.A., Mesnard, N.A., Serpe, C.J., Sanders, V.M., Jones, K.J., 2011. IL-
10 within the CNS is necessary for CD4+ T cells to mediate neuroprotection.
Brain Behav. Immun. 25, 820–829.
Xiong, Y., Mahmood, A., Chopp, M., 2009. Emerging treatments for traumatic brain
injury. Expert Opin. Emerg. Drugs 14, 67–84.
Xiong, Y., Mahmood, A., Meng, Y., Zhang, Y., Zhang, Z.G., Morris, D.C., Chopp, M.,
2012. Neuroprotective and neurorestorative effects of thymosin b4 treatment
following experimental traumatic brain injury. Ann. N. Y. Acad. Sci. 1270, 51–58.
Yenari, M.A., Han, H.S., 2012. Neuroprotective mechanisms of hypothermia in brain
ischaemia. Nat. Rev. Neurosci. 13, 267–278.
Yepes, M., Roussel, B.D., Ali, C., Vivien, D., 2009. Tissue-type plasminogen activator
in the ischemic brain: more than a thrombolytic. Trends Neurosci. 32, 48–55.
Yuan, J., Yankner, B.A., 2000. Apoptosis in the nervous system. Nature 407, 802–809.
Zhang, Z.G., Chopp, M., 2009. Neurorestorative therapies for stroke: underlying
mechanisms and translation to the clinic. Lancet Neurol. 8, 491–500.
Zhang, F., Wang, S., Gan, L., Vosler, P.S., Gao, Y., Zigmond, M.J., Chen, J., 2011.
Protective effects and mechanisms of sirtuins in the nervous system. Prog.
Neurobiol. 95, 373–395.
Zhang, L., Chopp, M., Meier, D.H., Winter, S., Wang, L., Szalad, A., Lu, M., Wei, M., Cui,
Y., Zhang, Z.G., 2013. Sonic hedgehog signaling pathway mediates cerebrolysin-
improved neurological function after stroke. Stroke 44, 1965–1972.
Zheng, W., Zhuge, Q., Zhong, M., Chen, G., Shao, B., Wang, H., Mao, X., Xie, L., Jin, K.,
2013. Neurogenesis in adult human brain after traumatic brain injury. J. Neurot
30, 1872–1880.
Zhou, J., Gennatas, E.D., Kramer, J.H., Miller, B.L., Seeley, W.W., 2012. Predicting
regional neurodegeneration from the healthy brain functional connectome.
Neuron 73, 1216–1227.
Zierath, D., Tanzi, P., Cain, K., Shibata, D., Becker, K., 2011. Plasma a-melanocyte
stimulating hormone predicts outcome in ischemic stroke. Stroke 42, 3415–
3420.
Zigmond, M.J., Smeyne, R.J., 2014. Exercise: is it a neuroprotective and if so, how
does it work? Parkinsonism Relat. Disord 20, 123–127.
Zipp, F., Aktas, O., 2006. The brain as a target of inﬂammation: common pathways
link inﬂammatory and neurodegenerative diseases. Trends Neurosci. 29, 518–
527.
